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1I. Abstract
Androgen-induced norepinephrine release in male accessory
sex organ smooth muscle growth and differentiation.
Julie M. Kim
The goal of this research was to determine the role of
norepinephrine (NE) in androgen-dependent pubertal
proliferation and adult terminal differentiation in normal
male accessory sex organ smooth muscle.  The guinea pig
seminal vesicle served as a model as its unique anatomy
allowed clean harvest of smooth muscle without epithelium.
Androgen significantly increased in vivo DNA
synthesis, total DNA, and NE release and down-regulated
protein kinase C (PKC) in prepubertal seminal vesicle
smooth muscle (SVSM) relative to prepubertal orchiectomized
controls.  High performance liquid chromotography
quantified NE release as an increased concentration of 1)
endogenous NE-metabolite, 3,4-dihydroxyphenolglycol per NE,
and 2) NE in vitro SVSM minces.  Binding studies using
[3H]RX821002, an α2-adrenoceptor antagonist, showed a
concurrent four-fold decrease in α2-adrenoceptor
concentration, indicating reduced feedback as a potential
mechanism for the increase in norepinephrine release.   In
vivo NE-depletion of > 99% by reserpine selectively
antagonized the androgen-induced increases in SVSM-DNA
2(measured spectrofluorophotometrically) and protein kinase
C (PKC) down-regulation (measured by γ[32P]ATP transfer).
Gel electrophoresis detected no apoptosis, supporting other
evidence that cell number is proliferation-dependent.  Cell
culture experiments demonstrated that SVSM α1-adrenoceptors
mediated the proliferative response to NE. Functional α1-
adrenoceptor expression, exhibited by electrical field
stimulation of SVSM neurons, correlated with the onset of
androgen-induced proliferative response.
In terminally differentiated adult SVSM, elevated NE
release and decreased α2-adrenoceptor concentration were
maintained from puberty and developed androgen-resistance.
PKC, however, returned to prepubertal castrate control
levels (Mariotti et al., 1992).  Androgen withdrawal
combined with NE depletion caused no reduction in adult
SVSM-DNA relative to adult castrates.  These findings
suggest that while increased NE release plays an obligatory
role in pubertal SVSM proliferation, NE release becomes
uncoupled from the mitogenic response at or before PKC
stable activation in adulthood.
Human benign prostatic hypertrophy (BPH) is a
fibromuscular neoplasia.  The data presented here suggest
BPH may be due to defective uncoupling between sustained,
3androgen-induced NE release and PKC activation.  New
pharmacological therapies for BPH can be envisioned based
on either antagonizing the reduction in presynaptic α2-
adrenoceptors to prevent increased NE release or inducing
PKC resistance to generate the normal amitotic state.
4II.  Literature Review
A.  Benign Prostatic Hypertrophy:  General Background
Benign prostatic hypertrophy (BPH) is primarily a
stromal neoplasia of the innermost aspect of the prostate.
The origin of the neoplasia is confined primarily to
periurethral tissue around the verumontanum, in proximity
to the cylindrical urinary sphincter that arises from the
bladder neck (Reischauer, 1925; Deming and Wolf, 1939;
Pradhan and Chandra, 1975; McNeal, 1978).  Glandular
epithelial tissue comprises approximately 20-30% of BPH
mass, whereas 70-80% is fibromuscular (Rohr and Bartsch,
1980).  Although the cause of BPH is not understood, the
adenoma is androgen and age dependent  (Huggins and
Stevens, 1940; Wu and Gu, 1987).
By examining random specimens at autopsy, benign
prostatic hypertrophy (BPH) has been found to begin as a
microscopic, non-symptomatic nodule as early as age 25-30
years of age when it has a prevalence of 10%.  With
advancing age, histological prevalence of BPH rises such
that by age 60, 70% of men are effected and by age 80, 90%
of men have histologically identifiable BPH (Arrighi et
al., 1991).  There is a lag period of approximately 5 years
in which 50% of microscopic BPH develops into macroscopic
5BPH that can be palpated through digital rectal examination
(Isaacs and Coffey, 1989).  Of these macroscopic nodules,
half will become clinically significant, meaning that only
25% of men with histologically identifiable BPH eventually
develop clinically relevant pathology (Lytton et al.,
1969).  However, on the basis that 25% of all men with
histologically identifiable BPH will need therapeutic
intervention, it appears that the probability that a 50-
year-old man will undergo medical treatment for BPH in his
lifetime is estimated to be 35% (Glynn et al., 1985).  The
high incidence of this neoplasia makes the development of
future pharmacological prophylactics for BPH prevention a
practical concept.
At clinical presentation of sympomatic disease, the
enlarged adenoma displaces the normal organ and weighs
between 60 and 100 grams, although weights of up to 200
grams have been seen.  These nodular enlargements encroach
upon the walls of the urethra, contributing to a set of
symptoms collectively termed clinical BPH.  Clinical BPH
symptoms include: 1) urethral compression causing
difficulty in urination and 2) urinary retention causing
subsequent bladder distension and hypertrophy.  These
secondary effects can then lead to tertiary complications
such as urinary tract infections, cystitis, renal
6infections, and decreased bladder continence due to
thinning of the bladder musculature.  The severity of
clinical, symptomatic BPH does not correlate with the size
of the adenomatous mass.  Additional pathologies may be
required for the presentation of clincally significant
disease.  For example, environment and genetic
predisposition (Ekman, 1989), lymphocytic infiltration
(Kohnen and Drach, 1979), infarcts (Franks, 1975),
nonandrogenic testicular factors (Sutkowski et al., 1993),
the stromal-epithelial interaction (Cunha, 1973), and a
variety of hormones and neurotransmitters have been
suggested to contribute to the development of BPH. None of
the above, however, have been shown to be directly
responsible for the development of adenomatous, smooth
muscle cell BPH as will be the focus of the research
presented here.
By 1989, the large number of men with clinical BPH
made procedures such as the transurethral resection of the
prostate (TURP) the second most common surgical procedure,
following cataract removal, for men 65 years of age and
older, costing the health care system more than five
billion dollars (Graversen et al., 1989).  This dollar
amount includes only surgical treatment of BPH and
overlooks widely prescribed medical treatments such as 5α-
7reductase inhibitors (finasteride), α1-adrenoceptor
antagonists (terazosin and doxazosin) and the newer, less
well-evaluated therapies such as thermoablation and stents.
Unfortunately, no treatment regimen has been highly
satisfactory to the patient.  The surgical treatments, TURP
and open prostatectomy, represent the most effective form
of treatment with 75-96% of patients reporting symptom
improvement and only a 2.2% reoperation rate (Oesterling,
1995).  Surgery also has the highest rate of severe
complications such as impotence in 5-10% and urinary
incontinence in up to 4% (Geller et al., 1995).
None of the various pharmacological therapies cure the
disease, but rather help to alleviate obstruction by
different mechanisms.  While the 5-α-reductase inhibitor,
finasteride, inhibits epithelial growth, the peak onset of
effect is 6-12 months after treatment.  Thirty percent of
men received some benefit as measured by symptom scoring
(Geller et al., 1995).  However, the change in symptom
score is only marginally different from placebo (2.6 vs 1
for placebo) (Lepor et al., 1996).  Side effects include
impotence and decreased libido. α1-adrenoceptor antagonists
reduce sympathetic tone around the bladder neck to improve
urinary outflow in 60-80% of patients within 4-6 weeks of
8treatment initiation.  However, 10% of patients suffer
adverse effects such as hypotension and headache (Jonler et
al., 1994).  All of the current pharmacological therapies
must be maintained chronically, since they only relieve
secondary symptoms in reversible fashion.
By the year 2000, forty million men will begin to
reach middle age (Bouvier and DeVita, 1991).  They
represent the largest population in history that will face
the problems of BPH.  (They also represent an enormous
market for pharmaceutical companies.)  There is a definite
need to develop more effective treatments for clinical BPH,
and even to ultimately develop a therapy for prevention of
the adenomatous growth.
B. Overview of Androgen Effects on Male Accessory Sex
Organs
Androgens effect a wide variety of target tissues such
as external and internal reproductive structures, sebaceous
glands, muscle and even the peripheral and central nervous
systems.  Androgenic effects range from the morphogenesis
of the male phenotype (Jost, 1953) to excitatory or
9maintenance actions on cellular growth and secretion via
androgen receptor-mediated induction of gene transciption
(Price and Williams-Ashman, 1961; Liao and Fang, 1970; Roy
and Chatterjee, 1995).
While much of the recent research of androgen action
has focused on genomic effects, nongenomic effects of
androgens at physiological concentrations have also been
identified within reproductive tissues.  These nongenomic
effects occur too rapidly to be compatible with changes in
mRNA and protein synthesis.  In general these non-genomic
effects have been implicated in signal transduction events
such as changing intracellular calcium concentrations and
effecting chloride flux in rat Sertoli cells (Revelli et
al., 1998).  Androgens may also function to modulate
biochemical reactions within some cells by serving as
coenzymes for the transfer of hydrogen between NADPH and
NAD (Talalay and Williams-Ashman, 1958).
Testosterone can diffuse passively into cells and can
either bind directly to the androgen receptor or can be
reduced to 5α-dihydrotestosterone (DHT) by reduction with
5α-reductase (Farnsworth and Brown, 1963; Bruchovsky and
Wilson, 1968).  DHT can also bind the androgen receptor and
will do so with greater affinity and stability than
testosterone itself (Krieg et al., 1976).  The gene coding
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for the androgen receptor is located on the X chromosome
and has been cloned (Lubahn et al., 1988). 5α-
dihydrotestosterone (DHT) binds the steroid binding domain
of the receptor.  Chaperone proteins such as heat shock
proteins then dissociate from the receptor, enabling the
activated receptor to dimerically bind DNA within the
nucleus at a specific DNA enhancer sequence called the
androgen-responsive element (Lindzey et al., 1994).
Testosterone also binds the receptor but has a diminished
effect on the tissue compared to DHT (Wenderoth et al.,
1983; Geller, 1990).  Upon binding to the androgen-
responsive element, the androgen receptor then can modulate
transcriptional activity ultimately effecting morphogenic
and other growth-promoting and stimulatory processes in
target tissues.
Most research on male accessory sex organs have
focused on androgen regulation of the epithelium.  However,
the clinical importance of the fibromuscular stroma in BPH
and the role of the mesenchyme in embryonic development of
male accessory sex organ (Cunha, 1973) has begun to focus
attention on the hormonal regulation of smooth muscle.
After castration, the rat ventral prostate epithelial cells
showed a 92% reduction in number and an 85% decrease in
cell size.  The fibromuscular stroma was also effected but
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to a lesser degree, showing a 39% decrease in cell number
and a 23% decrease in cell size.  Exogenous testosterone
replacement reversed these changes (DeKlerk and Coffey,
1978).  In this same organ, intra-acinar stromal cells
which may be smooth muscle cells, were unlike other
prostatic cells in that castration and androgen replacement
did not affect cell number (English et al., 1985).
Relevant to the focus of the research presented here,
were prior studies of androgen action on male accessory sex
organ fibromuscular stroma.  Mariotti et al. (1992)
examined the effects of castration and androgen replacement
on DNA in prepubertal and adult guinea pig seminal vesicle
smooth muscle.  Castration of prepubertal guinea pigs
prevented the postnatal development of the seminal vesicle
smooth muscle number as measured by DNA.  This development
was shown to be androgen dependent as the treatment of
these prepubertal castrates with dihydrotestosterone would
restore smooth muscle development.  Adult smooth muscle,
however, appeared to be terminally differentiated.  Neither
androgen depletion (castration) nor repletion had any
effect on adult smooth muscle cell number which were
similar to observations recorded earlier by English et al.
(1985).  Dihydrotestosterone’s actions on the seminal
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vesicle smooth muscle have been shown to be androgen
receptor mediated (Neubauer and Mawhinney, 1981).
Male accessory sex organs also contain estrogen
receptors which are concentrated in the fibromuscular
stroma (Belis et al, 1976; Neubauer and Mawhinney, 1981).
Estrogen treatment of castrate male guinea pigs induced
growth in smooth muscle tissue via an estrogen receptor
dependent mechanism (Mariotti and Mawhinney, 1981; Neubauer
et al.,1989). However, several lines of evidence have
indicated that estrogen is not of physiological
significance in this growth (Neubauer et al., 1981).
However, intraneuronal aromatization of testosterone to
estradiol in the medial preoptic area of male rats is
required for normal androgen effects on male sexual
behavior, and both dihydrotestosterone and estradiol are
required to generate normal virilization of this neural
site (Christensen and Clemens, 1975).  The extent to which
aromatization is involved in androgen action in peripheral
neurons is questionable.  However, neurosteroids, formed de
novo in neurons, have been identified in both central and
peripheral neurons (Jung-Testas et al., 1989; Melcangi et
al., 1990) and may modulate neurotransmission either
directly or through gene transcription.  The degree of
13
estrogen receptor involvement in male accessory sex organ
neurotransmission remains to be defined.
C. Autonomic Innervation of the Male Accessory Sex
Organs
In the human, the preganglionic sympathetic
innervation of the prostate is from the last 3 thoracic
(T10, T11 and T12) and first 2 lumbar (L1 and L2) segments
of the spinal cord.  These form 2 pathways, the superior
hypogastric plexus and the continuation of the pelvic
sympathetic trunks.  The preganglionic parasympathetic
innervation comes from the second through fourth sacral
spinal nerves to form the pelvic splanchnic nerves which
join other sympathetic hypogastric nerves to form the
inferior hypogastric plexus.  The sympathetic and
parasympathetic nerves form what is called the pelvic
plexus which innervates the pelvic organs as well as the
external genitalia.
The smooth muscle of the guinea pig seminal vesicle is
largely comprised of circularly oriented smooth muscle
cells with an additional longitudinal layer toward the
proximal, urethral end.  Based on light microscopy, both
smooth muscle layers are abundantly innervated with
14
catecholamine-containing nerves, which are particularly
concentrated at the base of the organs.  The sympathetic
adrenergic innervation originates from long preganglionic
hypogastric neurons which synapse with short postganglionic
neurons whose cell bodies are in the adventitia of the
seminal vesicle (Al-Zuhair et al., 1977).  Cholinesterase-
containing nerves are rarely encountered in the outer
layer, but can be identified in modest amounts in the
circular inner layer.  The submucosa and epithelia are rich
in cholinesterase-containing nerves, and catecholamine-
containing nerves are rare (Al-Zuhair et al., 1975).
Because the epithelium is cholinergically innervated and
has minimal to no adrenergic fibers, this tissue can
therefore serve as an indicator of androgenic responses
that have no direct link to cellular adrenergic
innervation.
By using agonists and antagonists in vas deferens, a
biphasic contractile response to electrical field
stimulation has been defined. This initial contraction has
been described as being ATP-mediated in the guinea pig vas
deferens (Burnstock et al., 1972; Westfall and Stitzel,
1978).  The latter component of the contractile response is
mediated by the post-junctional α1-adrenoceptor which was
abolished by prazosin in the rat vas deferens.  Rauwolscine
15
enhanced the contractile response, indicating the existance
of the pre-junctional α2-adrenoceptor which mediates
norepinephrine feedback (Brown et al., 1983).
Prostatic α1-adrenoceptors are found in the smooth
muscle.  At this time, evidence supports the existence of
three α1-adrenoceptor subtypes, A, B and D as well as
subtypes with high affinity (α1H) and low affinity (α1L) to
prazosin, which appear to be variants of the α1A-
adrenoceptors (Andersson et al., 1997).  Norepinephrine-
feedback-mediating α2-adrenoceptors also exist in several
subtypes, A, B, C and D.  The A and D subtypes are
considered to be species homologues (Bylund, 1995).
D.  Androgen Effects on Neurotransmission in Male
Accessory Sex Organs
Several studies have examined the effect of puberty on
the development of neurotransmission in the rat vas
deferens.  The post-natal development of α1-adrenoceptor
mediated contraction in the rat vas deferens coincided with
the large increase in endogenous androgen production at
16
puberty (Swedin, 1972).  Rauwolscine-induced enhancement of
electrically field stimulated rat vas deferens also did not
occur until the rat was pubertal (MacDonald and McGrath,
1984).  However, because of the lack of a prepubertal α1-
mediated response, it was not possible to determine whether
the function of the α2-adrenoceptor was also androgen
dependent.
More studies have linked androgens to the modulation
of adult adrenergic neurotransmission in target tissue
smooth muscle.  Twelve weeks after the castration of adult
Wistar rats, the adrenergic component of the contractile
response to electrical field stimulation was lost.
Spontaneous contractions that were not suppressed by
adrenergic antagonists, also developed post-castration.
Exogenous testosterone replacement daily for ten days
partially reversed this castration-induced loss of the
adrenergic contractile response and abolished the
spontaneous contractions (MacDonald and McGrath, 1980).
Total activities of tyrosine hydroxylase, the rate-limiting
enzyme of norepinephrine biosynthesis, as well as dopamine-
beta-hydroxylase, which catalyzes the last step of
norepinephrine synthesis were also shown to decrease per
pair of rat vasa deferentia after castration.  Neither
castration nor androgen repletion effected changes in
17
enzyme concentrations.  Norepinephrine content per pair of
rat vasa deferentia also fell but as was observed with the
contractile response, testosterone replacement reversed
these decreases such that norepinephrine returned to
control levels (Bustamante et al., 1989).
E.   Norepinephrine as a Component of Cell Growth in
Male Accessory Sex Organ Smooth Muscle
It is clinically established that α1-adrenergic
antagonists reduce smooth muscle tone and thus relieve some
of the obstructive symptoms of BPH, but any impact on
smooth muscle cell growth in human prostatic smooth muscle
has not been formally evaluated.  However, laboratory
research has demonstrated that catecholamines may play a
significant role in the proliferation of a variety of cells
including smooth muscle.
In 1989, Marino et al. established that norepinephrine
enhanced cellular proliferation in dividing fetal rat
cardiocytes.  The next year, it was reported that low
passages of subconfluent primary rat aorta cultures
exhibited an increase in DNA synthesis in the presence of
low concentrations of norepinephrine (1 nM) which was
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mediated through α1-adrenoceptors (Nakaki et al., 1990).  On
the other hand, a high concentration of norepinephrine (10
µM) inhibited DNA synthesis via β2-adrenoceptors, as
confirmed with β2-adrenoceptor agonist, isoproterenol
(Nakaki et al., 1990).  Later studies on primary cultures
of rat aortic smooth muscle showed that epinephrine-induced
increases in proliferation rate could be inhibited by α1-
adrenoceptor antagonist, prazosin, but not by α2- nor β-
adrenoceptor antagonists, yohimbine or propranolol (Mimura
et al, 1995).  Thus it was confirmed that catecholamine-
induced proliferation was an α1-adrenoceptor effect.
This enhanced proliferation is not limited to
cardiocytes and the vasculature.  Hepatocyte cultures also
showed proliferative effects due to catecholamines.
Epinephrine and norepinephrine were found to accelerate the
entry into S phase but inhibit cells if added in late G1.
Phenylephrine accelerated proliferation, but at a lower
rate (Refsnes et al., 1992).  It has also been shown that
α1-receptor blockade by prazosin abolished the twenty-four
hour peak of DNA synthesis in regenerating rat liver post
partial hepatectomy (Cruise et al., 1987).
The relationship between catecholamines and cell
proliferation has also been studied in atherosclerosis.
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Plasma adrenaline and noradrenaline levels in patients with
or without arteriosclerosis significantly and positively
correlated with the severity of vascular smooth muscle
thickening (Hauss et al., 1990).  It has also been shown
that prazosin and urapidil, α1-adrenoreceptor antagonists,
orally administered to rats whose carotid arteries were
experimentally injured with a balloon catheter reduced the
formation of neointima.  The formation of neointima, as
measured by DNA analysis, was significantly reduced in both
groups of rats, while the urapidil rats also showed
significant reductions in growth as morphometrically
measured in terms of area on histological cross-section.
These reductions in DNA and in cross-sectional area were
dose-dependent (Fingerle et al., 1991).
The role of catecholamines has been studied not only
in cellular proliferation, but also in apoptosis.  This has
resulted in some potentially conflicting hypotheses about
the role of norepinephrine.  Twenty-four hour
norepinephrine (10 µM) exposure in rat ventricular myocytes
in vitro was shown to decrease the number of viable
myocytes by 35% and to increase the percentage of apoptotic
cells two-fold (Communal et al., 1998).  Mouse spleen cells
and macrophages were also shown to undergo norepinephrine-
induced apoptosis in a dose-dependent manner (Josefsson et
20
al., 1996).  Another laboratory found that it was 3,4-
dihydroxyphenylglycolaldehyde (DOPGAL), a monoamine oxidase
A metabolite of norepinephrine, that induced apoptosis in
PC-12 (rat pheochromocytoma) cells, a model for adrenergic
neurons (Burke et al., 1997 and 1998).  The metabolite
DOPGAL, but not norepinephrine itself, was able to induce
apoptosis.  Communal et al. (1998) and Josefsson et al.
(1996), cited above, did not examine norepinephrine
metabolites in their studies.  On the opposing side is
research showing that norepinephrine reverses the apoptotic
effect of activin A in rat hepatocyte cultures (Zhang et
al., 1996), showing that more work needs to be done to
determine what is truly occurring.
While evidence has been accrued on catecholamine-
enhanced proliferation in organ systems such as the
vascular smooth muscle and hepatocytes, almost no work has
been done in the field of accessory sex organs such as the
prostate.  Determining what role catecholamines play in
accessory sex organ smooth muscle growth could provide
important clues in the understanding and treatment of
associated diseases such as BPH.
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F.   Norepinephrine and Transmembrane Signaling via α1-
Adrenoceptors of Protein Kinase C
Activation of α1-adrenoreceptors by norepinephrine is
known to activate a G-protein which then stimulates
phospholipase C (PLC) (Das, 1993).  PLC cleaves
phosphoinositol-bisphosphate (PIP2) which is a
phosphorylated derivative of phosphatidylinositol, a
phospholipid in cell membranes.  PIP2 cleavage results in
inositol 1,4,5-triphosphate which releases calcium from the
endoplasmic reticulum and activates calcium channels
(Larsson et al., 1984).  The other product of PIP2 cleavage
is diacylglycerol (DAG) which in turn temporarily activates
protein kinase C (PKC). The temporary activation of PKC
results in translocation of the enzyme from the cytoplasm
to the plasma membrane (Kishimoto, et al., 1980; Kraft and
Anderson, 1983).
Phorbol esters are often called tumor promoters
because of their ability to enhance cellular proliferation
leading to tumor formation.  Phorbol esters such as PMA
structurally mimic diacylglycerol (DAG).  DAG produces only
temporary association of PKC with the membrane due to
activation of sphingomyelinase (Kolesnick, 1987).
Sphingomyelinase activation can result in increased
22
concentrations of sphingosine which compete for the
regulatory unit of PKC and thus inhibit PKC activity
(Hannun et al., 1986).  However, relative to DAG, PMA can
stablely activate PKC which may be due in part to its
inability to activate sphingomyelinase (Kolesnick, 1987).
Stable activation of PKC was demonstrated in 1988 by the
addition of PMA to cultured neonatal rat cardiomyocytes.  A
five minute exposure to PMA doubled total PKC activity as
compared to the control.  By forty-eight hours, PMA
treatment of these neonatal cardiomyocytes resulted in a
down-regulation of total PKC activity to just 3% of control
(Henrich and Simpson, 1988).  It is thought that this down-
regulation is not a decrease in synthesis, but a result of
increased degradation by calpain, a calcium-dependent
protease (Young et al., 1987).  To summarize, unlike
temporary activation by diacylglycerol, phorbol esters lead
to stable activation of PKC, followed by cellular PKC
depletion and subsequently to cellular proliferation
(Hansen et al., 1990; Brooks et al., 1991).
Similarly to PMA down-regulation of PKC, activation of
α1-adrenoreceptors with 10 µM norepinephrine for 4 hours in
vascular smooth muscle cell culture down-regulated PKC (Hu
et al., 1992).  Although the decrease in PKC with prolonged
α1-adrenoceptor activation has not been directly related to
23
smooth muscle growth, there are many studies linking α1-
adrenergic effects to proliferation.  With this in mind, it
becomes a possibility that prolonged α1-adrenoreceptor
activation and down-regulated PKC are dependent upon one
another in association with proliferation.  This would fit
well with the hypothesis of this research linking
prepubertal, androgen-induced increased norepinephrine
release with, PKC down-regulation and male accessory sex
organ smooth muscle proliferation.
It is necessary to recognize the complexity within the
PKC superfamily.  Molecular cloning has identified and
characterized eleven PKC isoforms and has established that
PKC is a multigene family.  However, which PKC isozyme is
responsible for smooth muscle cell proliferation is still
being examined.  PKC isozymes α, β, δ, ε, γ, and ζ were
studied in cultured porcine aortic vascular smooth muscle
cells.  PKCα and PKCε were implicated as possible mediators
of G1/S cell cycle inhibition with PKCα predominating.  PKCα
down-regulated completely with PMA.  PKCε also down-
regulated in response to PMA, although not completely
(Sasaguri et al., 1993).  A later study using cultured rat
aortic vascular smooth muscle cells, quantified PKC
isoforms α, β and γ, and found PKCα was the only significant
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isoform associated with proliferation, also by down-
regulation (Haller et al., 1995).
Reduced amounts of total PKC activity (Mariotti et
al., 1992) and enhanced calpain activation (Gerbrosky et
al., 1997) also occur in response to androgen-induced
accessory sex organ smooth muscle proliferation (Mariotti
et al., 1992).  Prepubertal guinea pigs showed a doubling
of DNA and a drop in PKC in their seminal vesicle smooth
muscles in contrast to their adult counterparts.  Adult
guinea pigs showed no changes in PKC, calpain, or in DNA in
response to androgen.  However, normal adult seminal
vesicle smooth muscle which failed to proliferate with
androgen treatment, still continued to hypertrophy in
response to androgen, reflecting a selective loss in
proliferative ability in which PKC is resistant to changes
produced by androgen.  What remains to be explored is the
mechanism and potential link of PKC activation and
subsequent depletion to androgen regulation of
neurotransmission in male accessory sex organ smooth
muscle.
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G.   Rationale for the Use of Guinea Pig Seminal
Vesicle Smooth Muscle
Benign prostatic hypertrophy is a smooth muscle
neoplasia.  The goal of the research presented here is to
understand the normal mitogenic and terminal
differentiation mechanisms of androgen-dependent male
accessory sex organ smooth muscle cells. Understanding this
could ultimately be used to develop improved treatment and
preventative therapies to pharmacologically interfere with
the growth of the adenoma and the clinical presentation of
BPH.
Unfortunately, a good animal model for the study of
BPH does not exist and it has not been possible to
establish androgen-sensitive culture systems for normal or
neoplastic smooth muscle cells.  It should be recognized
that the true human prostate gland (the anterior, posterior
and lateral lobes) do not develop BPH.  It is the
periurethral, fibromuscular stroma that is the origin the
adenoma (Reischauer, 1925; Pradhan and Chandra, 1975).
Rodent male accessory sex organs do not exhibit spontaneous
prostatic hyperplasia.  The hormonal induction of
hypertrophy has never been achieved in the rat prostate,
and most mice strains show only marginal diethylstilbestrol
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induction of prostatic hyperplasia (Fingerhut and Veenema,
1966).  While aging dogs develop BPH, the neoplasia is
primarily a diffuse parenchymal hyperplasia.  Dog prostate
also does not show nodular growth that compresses
surrounding normal tissue, as seen in man (Moore, 1944).
Implants and xenografts of various prostate tissues
into hosts have also been tried in attempts to induce
abnormal growth.  Implantation of intact fetal urogenital
sinus into the ventral prostate gland of athymic mice
caused a 10-20 fold overgrowth within 4-9 weeks (Chung et
al., 1984), but it has been difficult to quantify changes
due to growth of the embryonic specimen versus the host
response.  Human BPH tissue xenografts in nude mice have
been explored.  But these xenografts are difficult to
maintain, show gradual atrophy and increasing squamous
metaplasia and have not been successfully maintained for
longer than 16 weeks (Debiec-Rychter et al., 1994).
Given the absence of a definitive animal model for
human BPH, androgen-dependent proliferation and
differentiation of normal accessory sex organ smooth muscle
was studied.  The long term goal was to develop a
hypothesis for the potential etiology and treatment of the
human neoplasia of the periurethral fibromuscular stroma.
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The guinea pig seminal vesicle was employed in this
investigation because of its unique anatomy.
Architecturally, the seminal vesicle is a cylindrical tube,
with a distinct inner epithelial layer and an outer smooth
muscular compartment.  The smooth muscle can be quickly
separated from the epithelium, leaving pure smooth muscle
specimens which can be employed in a variety of
experimental analyses.  This preparation was initially
employed by Levey and Szego (1955).
The normal guinea pig seminal vesicle smooth muscle
shows a prepubertal, androgen-sensitive state in which DNA
in smooth muscle cells increase, and an adult terminally
differentiated state that is selectively resistant in this
response to androgen (Mariotti et al., 1992).  Comparing
the prepubertal state in guinea pig seminal vesicle in
which DNA increases in response to androgen against the
adult which is resistant to androgen-induced proliferation
could uncover the mechanisms for normal accessory sex organ
smooth muscle growth and terminal differentiation.  Defects
in the normal terminal differentiation process for smooth
muscle tissue may prove to be an essential component in the
proliferation of accessory sex organ fibromuscular stroma
leading to human BPH.
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III.    Specific Aims
The long term goal of this research is to understand
norepinephrine’s role in the androgen-mediated
proliferation of male accessory sex organ smooth muscle and
to ultimately use this knowledge to develop possible
treatments and preventative therapies of benign prostatic
hypertrophy (BPH).  The working hypothesis of this research
is that androgen-dependent prepubertal proliferation of
male accessory sex organ smooth muscle is due to an
androgen-dependent increase in norepinephrine release and
down-regulation of PKC.  With this in mind, studies were
done to determine physiological relevance of norepinephrine
in the development of seminal vesicle smooth muscle, then
the mechanism by which norepinephrine release occurred,
using both ex vivo and in vitro experimental designs.
A.   Specific Aim 1:  Determine if androgen in vivo
induces the release of norepinephrine in seminal vesicle
smooth muscle in association with proliferation and is
resistant in terminal differentiation.
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B.   Specific Aim 2:  Determine the role of
norepinephrine as a mediator of growth in androgen-induced
proliferation of seminal vesicle smooth muscle.
1. Determine whether reserpine at maximal
norepinephrine-depleting doses in vivo selectively
antagonizes seminal vesicle smooth muscle
proliferation and PKC down-regulation in androgen-
treated animals.
2. Determine if norepinephrine in vitro stimulates
increases in cell number of seminal vesicle-derived
smooth muscle cells via α1-adrenoceptors.
3. Determine if norepinephrine may function anti-
apoptotically in seminal vesicle smooth muscle cells
to effect changes in cell number.
C.   Specific Aim 3:  Determine whether the androgen-
induced increase in norepinephrine release is due to a
significant reduction in the pre-synaptic feedback
inhibition of norepinphrine release.
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IV. Materials and Methods
A. In Vivo Orchiectomy and Hypogastric Nerve
Decentralization
Adult male Hartley guinea pigs (Hilltop) were
inhalationally anesthetized with metafane and underwent
scrotal route castration.  The skin incisions were closed
using stainless steel surgical staples.  Prepubertal, 5-7
day old, male Hartley guinea pigs (Hilltop) were
inhalationally anesthetized with ether and underwent
castration by midline abdominal incision.  In some animals,
hypogastric nerve decentralization was done simultaneously
with the castration by severing the hypogastric nerve
within the intestinal mesentery.  The hypogastric nerve was
positively identified prior to surgery with preliminary in
situ electrical stimulation of the hypogastric nerve
resulting in seminal vesicle contraction.  To close,
abdominal walls were sutured with silk thread, then the
skin was stapled together.
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B. Dihydrotestosterone, Estradiol, Testosterone, and
Reserpine Administration
After a ten day recovery period, 10 mg/kg of 5α-
androstan-17β-ol-3-one, aka. dihydrotestosterone (DHT)
(Sigma), 0.01 mg/kg of estradiol benzoate (E2B) (Sigma), or
10 mg/kg testosterone (Sigma) dissolved in peanut oil
(Planters), was administered subcutaneously.
These doses were chosen since it was previously
established that this dose was the maximally effective dose
to observe seminal vesicle smooth muscle growth in the
guinea pig (Neubauer and Mawhinney, 1981). Steroids were
administered for a minimum of one week since one week was
the time period established previously to show a
significant increase in DNA levels and DNA synthesis
(Mariotti et al., 1992).
Control groups received subcutaneous peanut oil only.
Reserpine (Sigma) was freshly prepared on each day of
use.  The varying concentratrations of reserpine were first
dissolved in 100 µl benzyl alcohol (Fisher) and 13.67 mg
citric acid monohydrate (Sigma) with slight heat.  500 µl
propylene glycol (Sigma) was then added and mixed. Water
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was used to q.s. to 5 ml.  Reserpine was then administered
intraperitoneally.
Control groups received intraperitoneally administered
vehicle only.
C. Harvesting of Seminal Vesicle Smooth Muscle Tissue
All guinea pigs were anesthetized by ether inhalation
then euthenized via cervical dislocation.  Seminal vesicles
were immediately removed at the bifurcation and
longitudinally opened.  Epithelia were carefully separated
by manual removal with a blunt scalpel, leaving clean
smooth muscle intact.  Both epithelia and smooth muscle
tissues were weighed.
D. Quantification of Norepinephrine Release
Norepinephrine release was measured both directly in
smooth muscle minces and indirectly ex vivo by DHPG/NE
ratios in samples from guinea pigs treated in vivo.  NE and
DHPG were quantified by HPLC.
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3,4-dihydroxyphenylglycol (DHPG) is the primary
norepinephrine metabolite found within the rat vas deferens
(Tarlov and Langer, 1971).  A previous study to determine
the metabolite spectrum in guinea pig seminal vesicle
smooth muscle indicated that DHPG was the predominant
metabolite and could be clearly detected using the method
described here (Johnson, 1996).  Previous studies
established that DHPG/NE ratio indicated norepinephrine
release (Graefe et al., 1972; Cubeddu et al., 1974).
Spontaneous release of [3H]norepinephrine was found to yield
primarily 3,4-dihydroxyphenylglycol in the rat vas deferens
(Graefe et al., 1972).  Electrical field stimulation of the
rat vas deferens also yielded 3,4-dihydroxyphenylglycol
(Cubeddu et al., 1974).  By using cocaine, it was
determined that the 3,4-dihydroxyphenylglycol formation was
the result of presynaptic metabolism by monoamine oxidase
of the released norepinephrine which was recaptured by
adrenergic nerve endings (Langer and Enero, 1974).
Storage-inhibiting agents like reserpine will also increase
the amount of 3,4-dihydroxyphenylglycol in tissue as a
result of the recapture and rapid presynaptic metabolism of
norepinephrine release from the disrupted granule (Cubeddu
and Weiner, 1975).
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Ultimately, it was determined that using the ratio of
the metabolite, 3,4-dihydroxyphenylglycol to norepinephrine
(DHPG/NE) did indirectly quantify norepinephrine release
(Graefe et al., 1972; Cubeddu et al., 1974; Langer and
Enero, 1974).
To quantify endogenous DHPG/NE, samples of seminal
vesicle smooth muscle were prepared by making 1.5%
homogenates using a McIlwain tissue chopper (0.25 micron2),
Brinkman Polytron (120 seconds at setting 4.5) and a
homogenate buffer containing 0.6% HClO4 (Fisher), 0.1%
sodium metabisulfite (Fisher), and 1.4 µM 3,4-
dihydroxylbenzylamine (Sigma) as an internal standard.
After centrifugation at 30,000 x g for 10 minutes, the
supernatant was syringe filtered through 0.45 µm Teflon
filters (Titan).  The filtrate was stored in
microcentrifuge tubes and frozen at –80oC until HPLC
analysis.  Samples, homogenates and filtrates were kept on
ice and protected from light.
To quantify NE release in vitro, NE was measured in
samples of media from seminal vesicle smooth muscle tissue
minces.  Smooth muscle was minced with a McIlwain Tissue
Chopper (0.25 micron2).  Minces were placed in 6 well tissue
culture plates in 2 mls Krebs-Henseleit buffer containing
1.13 M NaCl (Fisher), 47 mM KCl (Fisher), 25 mM CaCl2
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(Sigma), 12 mM MgSO4 (Fisher), 56 mM dextrose (Sigma), 11.8
mM KH2PO4 (Fisher) and 250 mM NaHCO3 (Fisher).  1.4 µM 3,4-
dihydroxybenzylamine was also added to the buffer to serve
as an internal standard.  100 µM ascorbic acid (Fisher), 1
µM desipramine (RBI) and 1 µM yohimbine (RBI) were added to
the Krebs-Henseleit buffer to prevent oxidation, reuptake
and feedback inhibition of released norepinephrine. Minces
were kept in an atmosphere of 95% oxygen and 5% carbon
dioxide.
Three 15-minute washes were initially done to remove
any norepinephrine released from the trauma of harvesting
and mincing.  Following this, 2-12 minute baseline media
samples were collected.  All samples were kept on ice,
protected from light then frozen at –80oC until HPLC
analysis.  On the day of analysis, samples were thawed,
kept on ice and protected from light.  Samples were probe
sonicated, syringe-filtered through 0.45 µm Teflon filters
(Titan), then analyzed by HPLC.
A mobile phase of 0.1 M NaH2PO4 (Sigma), 0.325 mM
octane sulfonic acid (Acros), 0.1 mM EDTA (Eastman Kodak),
and 0.25 mM triethylamine (Fisher), brought to pH 3.35 with
H3PO4 (Fisher) was pumped by a Waters 6000 pump at a flow
rate of 1.0 ml/min.  Samples or standards in 50-100 ul
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volumes were injected with a Waters U6K injector through a
Bioanalytical Systems (BAS) Phase II, 100 mm x 3.2 mm, 3 µm
particle size, C18 column.  Electrochemical detection using
a BAS  LC-4C detector was done under the following
parameters: +0.700 V, 10-50 nAmp range, and 0.10 Hz filter.
Results were charted on a Hewlett Packard 3395 Integrator
under the following parameters: threshold 5, attenuation 8,
chart speed 1, area reject 800,000.
Standard curves were established using 10, 80 and 160
pmols/50 ul of norepinephrine (RBI)and 3,4-
dihydroxyphenylglycol (Sigma) and 70 pmol/50 ul of 3,4-
dihydroxybenzylamine as an internal standard.
E. DNA Quantification for Seminal Vesicle Smooth Muscle
Treated In Vivo
DNA quantification followed the methods established by
Brunk et al. (1979).  Samples of smooth muscle were chopped
on a McIlwain tissue chopper (0.25 micron2), then
homogenized to a 5% homogenate using a Brinkman Polytron
(30 seconds, setting 3).  The homogenate buffer consisted
of 5 mM MOPS (pH 7.4), 1 mM dithiothreital (DTT), 2 mM
EDTA, and 1 mM EGTA.  After homogenization samples were
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sonicated for 1 minute using a Horn sonicator under the
following conditions: power 70, duty cycle 50, continuous.
All tubes are kept on ice.
The assay was done using a Shimadzu
spectrofluorophotometer at excitation 350 nm, emission 450
nm, band widths 5 nm, and low sensitivity.  Fisher Ultra-UV
microcuvettes were filled with 1.4 ml of buffer (100 mM
NaCl, 10 mM EDTA, 10 mM Tris 7.0) and 0.1 ml of 4’,6-
diamidino-2-phenylindole (DAPI) working dye (made from 0.06
ml of 1 mg/ml DAPI stock solution in 5 ml buffer).  Blank
readings were taken.  Readings following sequential 10 µl
additions of sample homogenates were then taken to
establish the linear stoichometric range for each sample.
Samples ranged in concentration from 0.1-0.3 µg of DNA/µl.
Standard curves were established using known amounts
of DNA (2, 4, 6, 8, and 10 µg).  DNA (Calf thymus—Sigma) was
prepared as a stock solution of 1 mg/ml in 0.01 N NaOH, and
were diluted to 0.2 mg/ml using buffer (100 mM NaCl, 10 mM
EDTA, 10 mM Tris 7.0) for the assay.
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F. Detection of Apoptosis by Gel Electrophoresis
In apoptosis, DNA fragments consisting of 180-200 base
pairs can be seen in a “laddering” pattern via agarose gel
electrophoresis (Wyllie, 1980).  This internucleosomal DNA
degradation by endonuclease is characteristically
associated with apoptosis and not with necrosis (Wyllie,
1980).  Therefore, to detect the presence of apoptosis,
agarose gel electrophoresis was used.
Seminal vesicles were harvested and the epithelia
removed.  Tissues were flash frozen in liquid nitrogen then
transferred to –80C until homogenization at a later date.
For homogenization, tissues were thawed by placing in ice
cold buffer containing 100 mM NaCl, 10 mM EDTA, and 10 mM
Tris 7.0.  A 2% homogenate was made by first chopping
tissues with a McIlwain tissue chopper then homogenizing
with a polytron.
DNA was extracted and prepared for agarose gel
electrophoresis in conjunction with Dr. Laura Gibson, in
the Department of Microbiology and Immunology at West
Virginia University.  Cells were lysed and protein digested
with proteinase K for 1 hour at 37oC.  Equal volumes of
chloroform and phenol were added.  The homogenate mixture
was shaken for 30 seconds then spun at 14,000 x g for 5
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minutes.  The aqueous phase was removed to a new tube and
1/10 volume of 3 M NaOAc and 1.5 volume of 100% ice cold
ethanol was added.  Precipitation occurred overnight at –
20oC.  The next day, DNA was pelletted by spinning at 14,000
x g for 15 minutes.  The pellet was dried, resuspended in
Tris-EDTA, treated with 5 mg/ml RNAse for 1 hour at 37oC,
extracted with an equal volume of chloroform, then respun.
The aqueous phase was removed and again precipitated using
ice cold 100% ethanol.
100 ng of sample DNA and 5 µl dye were loaded into the
wells of a 2% agarose gel containing 2% ethidium bromide
and covered with 0.04 M tris-acetate, 0.001 M EDTA buffer.
The first lane contained a positive control Kb ladder
(Gibco BRL) while the last lane contained a negative
sample.  The power supply was applied for 2 hours at 90 mV.
The gel was then exposed to UV light and photographed with
a Strategene Eagle Eye II camera.
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G.  Seminal Vesicle Smooth Muscle Cell Cultures
Male Hartley guinea pigs were sacrificed and submerged
in 70% ethanol before the seminal vesicle was harvested and
the epithelia removed.  The clean smooth muscle tissue was
then minced in a petri dish containing 1 mg/ml filter
sterilized collagenase (Sigma) in Dulbecco’s Modification
of Eagle’s Medium (DMEM) (Cellgro) or Hanks Balanced Salt
Solution (Sigma) with no bovine serum, and incubated for
one hour at 37oC.  The sample was then triturated with
decreasing pipet size to 5 ml then transferred to a 50 ml.
tube to settle at unit gravity.  The pellet was
reconstituted in DMEM containing 292 µg/ml L-glutamine
(Sigma), 50 µg penicillin/ml (Sigma), 50 µg streptomycin/ml
(Sigma), 150 µg neomycin/ml (Sigma) and 10% heat inactivated
fetal calf serum (Biowhittaker).  The supernatant was
harvested and spun on a Sorvall RT 6000B centrifuge (speed
3).  The resultant pellet was also reconstituted in culture
medium.  Two separate cultures were made with the two
reconstituted pellets.  Cells were then grown in flasks
(Costar) in an incubator at 37oC, and 5% CO2.  Previous
studies established that cultures appeared to be pure
smooth muscle cells based on double staining for nuclei
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(DAPI) and immunocytochemical staining for smooth muscle
isoactin (Gerbrosky et al., 1997).
Cells were passed every 2 weeks and grown in media
containing 5% fetal bovine serum (Gibco).  Cells were
harvested by first removing media and any detached cells,
rinsing with HBSS, and trypsinizing (Sigma) for 2 minutes
followed by mechanical removal with a rubber policeman to
remove attached cells.  Media containing 10% fetal bovine
serum was used to stop trypsinization.
For in vitro proliferation studies, six-well culture
plates (Costar) were used.  Each well was plated with 6-7 x
104 cells/well as determined by hemocytometer, and incubated
for 24 hours to allow attachment.  Treatment groups were
then exposed to various agents such as: 1 µM phenylephrine
(Sigma) in 0.1% ethanol, 10 µM phenylephrine in 0.1%
ethanol, 1 µM prazosin (Sigma) in 0.1% ethanol, 1 µM
isoproterenol (RBI) in water, and 100 µM ascorbic acid
(Fisher).
Note: Although phenylephrine is freely soluble in
water as well as ethanol, experiments using water vehicle
did not show any effect of phenylephrine on cells.
42
Control cells were exposed to 0.1% ethanol or water
and 100 µM ascorbic acid.  Media and agents were replaced
daily.  Cells were counted using a hemocytometer.
H. Organ Bath Electrical Field Stimulation
Seminal vesicles from male Hartley guinea pigs treated
in vivo were harvested.  Adventitia was removed, the lumen
opened lengthwise and the epithelia removed.  Proximal
segments of longitudinal smooth muscle were mounted between
two platinum electrodes for electrical field stimulation
(Grass S44) and attached to a force displacement transducer
(Grass 79D) for isometric contraction recording. The
proximal 1.5 cm for adult and 1.0 cm for prepubertal guinea
pigs were used in the organ bath due to the inability of
the bath to contain an entire longitudinal adult seminal
vesicle smooth muscle.  Proximal ends were used since
longitudinal smooth muscle was more prevalent proximally
than elsewhere (Al-Zuhair et al., 1975).  Preparations were
placed in an organ bath containing Krebs-Henseleit buffer,
kept at room temperature and continuously bubbled with 5%
CO2 and 95% O2.  Tissues were given 1 hour to equilibrate at
an initial tension of 2 grams.
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After equilibration, tissues were electrically field
stimulated for 30 seconds at 40 V with train pulses of 0.5
msec. duration, 0.01 msec. delay at varying Hz (2, 5, 10,
20, 30 and 40 Hz).  Contractile response was shown to be
graded between 2 and 20 Hz, and 30 Hz was previously shown
to stimulate supramaximal contraction without causing
significant exhaustion (LaPierre et al., 1993). Organ bath
contents were drained and replaced 5 minutes after
stimulation was initiated.  Tissues were not stimulated
again until 15 minutes had passed.  After all the seminal
vesicle segments were stimulated at 2, 5, 10, 20, 30, and
40 Hz, segments 1 µM rauwolscine (RBI) was added to the
Krebs-Henseleit buffer and segments were allowed to
equilibrate for 1 hour.  Tissues were then restimulated at
the various Hz.  1 µM prazosin was then added to the buffer
and tissues equilibrated again for 30 minutes before
receiving a final 40 Hz stimulation.  1 µM prazosin was
found in preliminary dose response studies to maximally
inhibit the adrenergically-mediated, electrically-field-
stimulated contraction.
For the study of post-junctional α2-adrenoceptors,
tissues were prepared as above.  However, rather than
electrical stimulation, 10 µM BHT-933 [6-Ethyl-5,6,7,8-
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tetrahydro-4H-oxazolo[4,5-d]azepine-2-amine
dihydrochloride], a selective α2-adrenoceptor agonist (RBI),
or 10 µM methoxamine + 0.1 µM prazosin were used to elicit
contraction.
I. α2-Adrenoceptor Characterization and Quantification
Ligand binding studies using [3H]RX821002 [2-methoxy-
1,4-[6,7-3H]benzodioxan-2-yl-2-imidazolin HCl] (Amersham)
were done to identify, characterize and quantify the α2-
adrenoceptor in prepubertal and adult 7-day-
dihydrotestosterone-treated, normal and castrate  guinea
pigs.  The ligand RX821002 is an α2-adrenoceptor antagonist
which exhibits relatively high affinity for all the α2-
adrenoceptor subtypes (O’Rourke et al., 1994).  RX821002 is
the 2-methoxy analog of idazoxan. In rabbit and human
frontal cortex, idazoxan binds with comparable affinity to
α2-adrenoceptors and phentolamine-displacable non-
stereoselective sites (Convents et al., 1989).  In these
same tissues, the 2-methoxy analog of idazoxan,
[3H]RX821002, was shown to have a 10-fold higher affinity
for the α2-adrenoceptor (Kd = 2.8 nM) than [3H]idazoxan (Kd =
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24 nM) and equal affinity with [3H]rauwolscine (Vauquelin et
al., 1990).
Seminal vesicles were freshly harvested, and the
adventitia and epithelia were removed.  Seminal vesicle
smooth muscles were then chopped on a McIlwain tissue
chopper to 0.5 micron2 followed by teflon glass
homogenization on ice in a 0.32 M sucrose solution
containing 5 mM Tris buffer at pH 7.4.  A Brinkman polytron
was then used to further homgenize the sample.
Homogenates were centrifuged at 1000 x g for 10
minutes.  The supernatants were saved and the pellets were
rehomogenized and re-spun as previously described.  The
supernatants were then pooled, centrifuged at 48,000 x g
for 20 minutes, and the resultant supernatant was
discarded. The synaptic membrane pellet was then
reconstituted in 25 mM sodium phosphate buffer by using the
Brinkman polytron (Deupree et al., 1996).
Bradford protein determinations were done on this
reconstitution.
Kinetic studies were done to establish protein
dependence and equilibration with time of incubation using
0.4 nM [3H]RX821002, the lowest ligand concentration
employed in saturation analysis.  The analyses for protein
dependence and equilibration time were quantified for total
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rather that saturable binding to ensure valid [3H]RX821002
binding conditions for all potential components of binding.
For α2-adrenoceptor saturation binding experiments,
0.40 to 9.0 nM of [3H]RX821002 were added to membrane
suspensions and sodium phosphate buffer was added for a
final total volume of 200 µl.  Reactions were allowed to
equilibrate for 20 minutes at room temperature.  Saturable
binding was determined with a parallel set of reactions
that also contained 10 µM rauwolscine.  Rauwolscine was
initially employed because the non-tritiated RX821002 was
commercially unavailable at the time.  10 µM of rauwolscine
represented the minimum concentration of rauwolscine
necessary to produce greater than 90% inhibition of 5 nM
[3H]RX821002 binding.  Subsequently, non-radioactive
RX821002 became commercially available.  When tested,
RX821002 at 1x10-7 M generated the same degree of maximum
inhibition as 10 µM rauwolscine at 5 nM [3H]RX821002
binding.
 To assess ligand binding specificity, competition
experiments were done using 5nM [3H]RX821002 and varying
concentrations of prazosin (Sigma), phentolamine(Sigma),
clonidine , 5HT, rauwolsince (RBI), and 2-methoxyidazoxan
(Sigma).  Assays were given 20 minute equilibration time.
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Membrane suspensions were then filtered through sodium
phosphate presoaked Whatman GF/B glass fiber filter papers
with a 10-well minifold (Fisher).  Filters were rinsed with
sodium phosphate buffer and the trapped radioactivity was
counted by liquid scintillation (ScintiSafe by Fisher)
photometry.
Scatchard-Rosenthal plots were used to determine Kd and
Bmax values.  IC50 values were converted to Ki values using
the Cheng and Prusoff equation:
     IC50___________
KI =      free 3H-ligand
1 +  Kd of 3H-ligand
J.  PKC Analyses
Tissues were homogenized (Brinkman Polytron setting 3,
30 seconds, three times with 30 second intervals) in 20 mM
MOPS (pH 7.4) containing, 2 mM DTT, 1 mM EDTA, 1 mM EGTA,
100 µg/ml leupeptin, 10 µg/ml aprotinin, 10 µg/ml
chymostatin A, 10 µg/ml antipain and 1 mM
phenylmethanesulfonyl fluoride (PMSF). Homogenates were
then centrifuged at 10,000 x g for 10 minutes to sediment
nuclei and unbroken cells.  This pellet was then
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resuspended, rehomogenized in the above buffer, and
recentrifuged.  The supernatants of the original spin and
of the subsequent spin were combined and centrifuged at
100,000 x g for 60 minutes to generate the EGTA soluble
fraction.
To assay the protein kinase, the EGTA-soluble fraction
was column fractionated on DEAE-cellulose.  Assays were
performed at 30oC using a reaction mixture of 100 µl
containing 40 mM MOPS (pH 7.2), 5 mM MgSO4, 1 mM DTT, 20 µM
α[32P]ATP (0.5 µCi), and 600 µg protamine.  Cyclic AMP-
dependent type I and type II kinases were assayed by
reaction with and without 10 µM cAMP, using 200 µg of
histone f2b as a substrate.  After a 5 minute incubation at
30oC, duplicate 40 µl aliquots were spotted onto 2.3 cm
squares of P-81 phosphocellulose paper and immersed in 1%
sodium pyrophosphate, followed by three 15 minutes washes
in the same fluid, a 95% ethanol rinse and a 3:1 v/v 95%
ethanol:ether rinse.  Disks were air-dried then counted in
a liquid scintillation spectrophotometer (Durham et al.,
1986).
To further isolate particular PKC isozymes, peak
enzymatically active fractions from the DEAE column were
pooled and loaded in Minifold I (Schleicher & Schuell)
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wells.  Total proteins from these individual fractions were
identical between groups based on Bradford protein analysis
of the individual fractions and the pooled sample.  The
Minifold contained Immobilon P (PVDF) (Millipore) membrane
wetted underneath with one sheet of Gel Blot (GB002)
(Schleicher & Schuell). 500 µl samples with protein ranging
from 1.5 to 25 µg were applied.  The membrane was prepared
following Tropix, Inc. Western-Light Chemiluminescent
Detection System Protocol.  Primary mouse monoclonal anti-
PKC antibodies (Transduction Labs) were applied to the
membrane in a concentration of 2 µg/ml in a 90 minute
incubation.  Unbound primary antibody was rinsed off before
a 90 minute incubation in secondary Donkey anti-mouse IgG,
alkaline phosphate-conjugated antibody in a 1 : 5000
dilution with buffer containing 0.2% I-Block (Tropix), 0.1%
Tween-20 and 1/10th volume PBS.  Unbound antibody was again
rinsed off and Ultra-Pure CSPD chemiluminescent substrate
(Tropix) was applied.
Chemiluminescence was recorded on Kodak X-OMAT film
and analyzed and quantified by Optimus densitometer.
Antibodies were used to detect PKC isozymes α, β, δ, ε, γ,
θ, and ξ.  Isozymes α, ε, γ, θ, and ξ were detectable in
appreciable quantities. The β and δ isozymes were either
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undetected or detected only in trace amount unquantifiable
by densitometry.  The ε, θ, and ξ isozymes demonstrated wide
intra-assay variation and were not subsequesntly pursued.
Only the α and γ isozymes exhibited a stoichiometric
relationship between protein concentration and
chemiluminescence and thus were the 2 isozymes quantified
in this study.  In preparation for PKCα isozyme
quantification by dot blots, a protein dependence study was
done using seminal vesicle smooth muscle from prepubertal
and adult castrates and PKCα.  Although not
stoichiometrically linear, relative density did increase
with increased protein applied in a linear fashion.  For
prepubertal castrates, the amount of protein (x) was
related to chemiluminescent density (y) such that
y=0.022x+0.671 with correlation r2=0.80.  In adult
castrates, y=0.019x+0.228, r2=0.97.  This showed that
chemiluminescent density would be dependent upon the amount
of protein applied.
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K.  Statistical Analyses
Statistical analyses, generally one-way analysis of
variance, Students t-test or Tukey-Kramer’s test were
employed in this work.  Statistical significance was
defined at p < 0.05.  Graphs were done using JMP
Statistical Software, Microsoft Excel 97, or GraphPad.
V.   Results
A.  Specific Aim 1: Androgen in vivo induced increased
norepinephrine release in the seminal vesicle smooth muscle
of prepubertal castrates.
As shown in previous studies of rat vas deferens
(Tarlov and Langer, 1971;  Graefe et al., 1972; Cubeddu et
al., 1974), the predominant metabolite of norepinephrine
(NE) in the guinea pig seminal vesicle smooth muscle was
found to be 3,4-dihydroxyphenylglycol (DHPG) (Johnson,
1996).  By using [3H]norepinephrine, it was found that more
than 70% of the spontaneous outflow of NE in rat vas
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deferens was deaminated to DHPG, with the next highest
metabolite via catachol-O-methyltransferase, accounting for
14% (Graefe et al., 1972).  DHPG was positively identified
by comparison of retention times with known DHPG standard
on HPLC.
The use of endogenous DHPG/NE ratio has been used as
an indicator if in vivo NE release.  Prepubertal guinea
pigs treated in vivo for 7 days with 10 mg/kg
dihydrotestosterone (DHT) showed a tripling of endogenous
DHPG/NE over oil-treated prepubertal controls in seminal
vesicle smooth muscle homogenates (fig. 1).
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Figure 1:  Effects of DHT on DHPG/NE in seminal vesicle
smooth muscle
*
Figure 1: Norepinephrine release in prepubertal (PP)
seminal vesicle smooth muscle, as measured by DHPG/NE,
increased three-fold with 10 mg/kg DHT replacement as
compared to prepubertal castrate (c) control.  DHT-treated
prepubertal ratios were similar to adult levels which were
resistant to androgen-induced change.  In prepubertal
animals, castration was done prepubertally at 6-7 days of
age. Adults were castrated at approximately 500 grams or at
800 grams.  Prepubertal groups had n=8-15, weighing approx.
250gms. Adult groups had n=4-8.
*p < 0.05 compared to all other groups.
Norepinephrine release in adult guinea pigs showed no
change with DHT treatment and were similar to levels
measured in prepubertal castrates treated with DHT for 7













































elevated by androgen, it remained elevated into adulthood
when it was no longer dependent upon androgens.
The effect of other sex steroids on norepinephrine
release was also examined.
Figure 2: The Effect of Various Sex Steroids on
Norepinephrine Release in Seminal Vesicle Smooth Muscle
 *
  *
Figure 2: Prepubertal guinea pigs were castrated at 6-7
days of age.  10 mg/kg of dihydrotestosterone (DHT) and
testosterone (T), 0.01 mg/kg estradiol benzoate (E), or oil
(control) were given daily for 7 days. n=6-15
*p < 0.05
Previous evidence demonstrated that the actions of













































































depended upon its aromatization by 5α-reductase and the
combined effects of the resultant dihydrotestosterone and
estradiol (Christensen and Clemens, 1975).  Estradiol was
also known to stimulate increased seminal vesicle smoooth
muscle DNA (Mariotti and Mawhinney, 1981).  Therefore,
estradiol was examined with the hypothesis that it may
interact with dihydrotestosterone in norepinephrine
release.  While norepinephrine release was increased in
response to estradiol, there was no significant interaction
with dihydrotestosterone (fig. 2).  The effects of
testosterone were duplicated by dihydrotestosterone alone
in prepubertal castrate animals.  This was consistent with
other parameters examined in seminal vesicle smooth muscle
(Neubauer and Mawhinney, 1981).  Dihydrotestosterone alone
was thus the androgen employed as it would eliminate the
question of estradiol involvement in any androgenic effect.
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Figure 3:  Effects of DHT on DHPG and NE concentrations in
prepubertal and adult seminal vesicle smooth muscle
**
  *
Figure 3: The absolute numbers here were used to calculate
the ratios in Fig.1.  In prepubertal castrates,
norepinephrine (NE) was released and no longer contained
within the smooth muscle, resulting in a drop in NE
concentration.  However, due to the increased NE release,
the concentration of metabolite DHPG increased within the
tissue.
*p < 0.05
** p < 0.05 compared tp PP-c
Evaluating the individual components of the DHPG/NE
ratio (fig. 1) revealed that dihydrotestosterone (DHT) had
opposite effects on the concentrations of DHPG and
norepinephrine (fig. 3).  This pattern of change was
expected since the release of norepinephrine would cause



































































































stored amount of parent norepinephrine may be diminished.
Once again, DHT-treated prepubertal tissues showed similar
concentrations of DHPG and NE as measured in adult castrate
and adult DHT-treated castrate tissues, indicating NE
release was sustained at relatively high levels and became
androgen-resistant in adults.
Simultaneous experiments were also done to examine the
question of whether severing the preganglionic nerve supply
to the guinea pig seminal vesicle antagonized the DHT-
induced norepinephrine release during the proliferative
phase of growth. Decentralization of the hypogastric nerve
was performed and confirmed by the lack of seminal vesicle
contraction in response to directly applied electrical
stimulation of the hypogastric proximal to the severed
nerve in situ.
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Figure 4:  Hypogastric nerve decentralization did not
effect DHPG/NE, DHPG or NE
Figure 4: Castration (C) and decentralization (d) were done
during the same surgery on days 6-7 of age. n=8-15. There
were no significant differences due to decentralization.
Decentralization did not inhibit norepinephrine release as
measured by DHPG/NE ratio in prepubertal guinea pigs (fig.
4).  This suggested that basal norepinephrine release was
also not effected by decentralization and further indicated
that androgen-induced neurotransmission was localized to
the post-ganglionic fiber.
A time course of the DHPG/NE ratios in prepubertal
castrates, completed prior to the research presented here







































































































begin on the third day of DHT treatment and peaks at day 5
of treatment.  The ratio continued to be elevated to the
seventh and last day of treatment.  The increases in these
studies showed the same magnitude as recorded in this
present investigation (fig. 5).
Figure 5: Time course of measured NE release in seminal
vesicle smooth muscle homogenates from prepubertal
castrates treated with DHT
 *
    *
   *
Figure 5:  Norepinephrine release (DHPG/NE) increased
significantly on day 3, peaking by day 5.  (Data by E. A.
Johnson, 1996).
*p < 0.05 compared to castrate control.
These ex vivo measurements of norepinephrine release
from the homogenates were then compared and confirmed with





































measured from the incubation media from minces of in vivo
androgen-treated, prepubertal castrate seminal vesicle
smooth muscle.  Direct measurements of norepinephrine from
the minces also eliminated any questions regarding systemic
norepinephrine.  Ascorbic acid, desipramine and yohimbine
were added to the buffer to prevent oxidation, reuptake and
feedback inhibition of released norepinephrine
respectively.
Basal release, rather than electrically or potassium
stimulated release, was of interest in an attempt to relate
the findings to proliferation and differentiation.  Maximal
nerve activity from electrical or potassium stimulation was
not pursued since it would more closely resemble the nerve
activity seen post-pubertally during ejaculation.  To
ensure release, rather than leakage due to trauma, was
being measured, three 15-minute washes were done prior to
collection.
A preliminary study using adult normal seminal vesicle
smooth muscle was done to show that norepinephrine released
into the 2ml of media was proportionate to the amount of
smooth muscle.  Using 134 mg and 226 mg of smooth muscle,
the NE released into the media were 39.48 and 78.42 pmoles
respectively, indicating 0.29 and 0.35 pmole of NE released
per mg tissue.
61
Figure 6: The effect of DHT on baseline norepinephrine
release as measured directly in prepubertal castrate minced
seminal vesicle smooth muscle
    *
Figure 6: Prepubertal castrate guinea pigs (approx. 250
gms) were treated in vivo then seminal vesicle smooth
muscle was harvest and minced. Minces underwent 3-15 minute
washes, then the Krebs-Henseleit buffer was collected as
the baseline after a 12 minute, post-wash interval.
Norepinephrine was quantified by HPLC.  Release was
expressed as norepinephrine released into the media per
norpinepinephrine within the tissue.  n=3.
*p < 0.05 compared to all other groups.
Norepinephrine release in the minces increased with
DHT-treatment showing a similar time-course as demonstrated
above in figure 5.  Androgen treatment caused release to
increase significantly by day 3.  Release remained high on
days 5 and 7 although it was not significantly different
from control.  The percentage of initial norpepinephrine
within the tissue which was released into the media during



















the point of collection was as follows: control=5.9%, 1-day
DHT=4.0%, 3-day=15.2%, 5-day=11.8%, and 7-day=11.4.  Figure
5 showed peak release on day 3 and ex vivo data showed
increased release on day 5.  This may be due to ex vivo and
in vitro differences in metabolic activity, pathways and
uptake.
B.  Specific Aim 2: Norepinephrine mediated androgen-
induced proliferation of seminal vesicle smooth muscle in
vivo.
1. Reserpine at the minimum dose to maximally deplete
norepinephrine in vivo selectively antagonized
seminal vesicle smooth muscle proliferation and PKC
down-regulation in androgen-treated animals.
Previous studies have shown that 7 day treatment with
10 mg/kg dihydrotestosterone in prepubertal guinea pigs
caused proliferation of the seminal vesicle smooth muscle
as measured by DNA content (Mariotti et al., 1992).  The
results presented above, indicated that norepinephrine
release was increased with androgen treatment in
prepubertal guinea pigs concurring with a similar time
course of increased DNA synthesis.  In adults, NE release
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was androgen-resistant under conditions in which cell
number was also androgen-resistant (Mariotti et al., 1992).
To address the question of whether NE mediated the
androgen-induced proliferation of seminal vesicle smooth
muscle, in vivo experiments were done using the drug
reserpine which depletes norepinephrine by disrupting
storage and uptake into the granule (Bertler et al., 1961).
Because norepinephrine is co-transmitted with adenosine
triphosphate (ATP) (Burnstock et al., 1972), there was some
concern that ATP may be effected by reserpine.  However,
studies showed that reserpine at maximum norepinephrine-
depleting dosages did not affect ATP (Kirkpatrick and
Burnstock, 1987).
Preliminary studies showed that a single dose of
reserpine at 0.30 mg/kg depleted seminal vesicle smooth
muscle norepinephrine to levels undetectable by HPLC for 48
hours in 100% of animals.  By 72 hours, norepinephrine
levels began to rise.  However, the crucial study was to
determine the regimen of reserpine treatment in androgen-
treated and control animals to deplete norepinephrine
during an entire 5-day course of treatment.
Reserpine dose-response studies were done in androgen-
treated and control groups to determine the minimum dose of
reserpine necessary to maximally deplete norepinephrine to
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undetectable levels as quantified by HPLC in seminal
vesicle smooth muscles of 100% of the animals.  Time
studies were also done to determine the appropriate
reserpine dose necessary to deplete norepinephrine during
the entire treatment regimen.
Table 1: 24 hour Reserpine Dose Response in Prepubertal
Oil-treated Castrate Controls
Reserpine given % NE depleted
   0.05 mg/kg (n=3)    0
   0.15 mg/kg (3)      80
   0.25 mg/kg (3)      100
   0.50 mg/kg (3)      100
Table 1: HPLC analysis indicated that 0.25 mg/kg reserpine
i.p. was necessary to deplete NE to undetectable levels in
seminal vesicle smooth muscle in all prepubertal castrate
control animals.  This 0.25 mg/kg dose was also used to
pre-treat DHT-treated animals 24 hours prior to the first
DHT administration.
Time course studies were done during which HPLC
analysis was done after 48 hours, 72 hours, 4 days and 5
days of daily reserpine treatment.  These studies showed
that 0.25 mg/kg reserpine, i.p., given daily, depleted
norepinephrine to levels undetectable by HPLC in seminal
vesicle smooth muscle in 100% of oil-treated castrate
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control animals for the entire 5 day oil-treatment regimen
(not shown).  This regimen had no significant effect on
castrate seminal vesicle smooth muscle DNA (SVSM-DNA) (fig.
7).
Figure 7:  The Effect of  5-day, 0.25 mg/kg Reserpine
Treatment on Seminal Vesicle Smooth Muscle (SVSM)-DNA in
prepubertal castrates
Figure 7:  0.25 mg/kg reserpine, i.p. daily for 5 days did
not significantly reduce DNA (µg) content in seminal vesicle
smooth muscle in prepubertal castrates.
Animals treated with 10 mg/kg dihydrotestosterone
(DHT) were found to require a higher dose of reserpine to
deplete norepinephrine for the entire 5 days of DHT
treatment regimen.  When initially given the same
0.25mg/kg/day dose, it was noticed that DHT-treated animals





















as lethargy, diarrhea and weight loss, compared to
reserpine-only groups.  Dose response studies were repeated
for guinea pigs treated with androgen for 1, 3 and 5 days.
It was determined that after a pretreatment 0.25 mg/kg
reserpine dose, 0.75 mg/kg of reserpine given daily
intraperitoneally was necessary to deplete norepinephrine
in 5 day, DHT-treated guinea pigs.  Hence, oil-treated
controls were also pretreated with 0.25 mg/kg reserpine.
The reason for the discrepancy in reserpine doses in
DHT versus oil-treated controls was not explored.  The
important issue was to determine the minimum dose of
reserpine necessary to deplete seminal vesicle smooth
muscle norepinephrine to levels undetectable by HPLC in
100% of animals within the treatment groups.
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Figure 8: Effect of Norepinephrine-Depletion on Androgen-
Induced Seminal Vesicle Proliferation
 *     *
   **  * *
 ***
   * *
Figure 8: Animals were castrated and decentralized at 6
days of age.  After a 10 day post-castration recovery
period, animals were pretreated with 0.25 mg/kg reserpine,
i.p., or with vehicle.  24 hours after the pretreatment, 10
mg/kg dihydrotestosterone (DHT) or oil treatment, and 0.75
mg/kg reserpine or vehicle was given daily for 5 days.
Epithelium, which is cholinergically innervated, was not
effected by NE depletion. Control n=5. DHT n=7.
DHT+reserpine n=14.
*p < 0.05 compared to control.
**p < 0.05 compared to control and DHT-treated.
***p < 0.05 compared to DHT-treated.
The data show that norpinephrine depletion by
reserpine had no significant effect on androgen-induced
epithelial growth as measured by wet weight and DNA.  The
unperturbed epithelium also served as a control for any
non-specific and anti-androgenic effects of reserpine.
tissue weight
































Because the epithelium is primarily cholinergically
innervated, agents acting selectively upon adrenergic
innervation would not be expected to affect the epithelium.
It has been confirmed in mouse brain that reserpine in vivo
did not affect acetylcholine levels (Palfai et al., 1986).
Norepinephrine-depletion did affect the adrenergically
innervated smooth muscle compartment. Norepinephrine-
depletion reduced the androgen-induced increase in wet
weight by 31% and in DNA content by 42% without causing a
change in cell size as measured by RNA/DNA ratio (0.0014 +
0.0003 for DHT versus 0.0018 + 0.0003 for DHT+reserpine).
In androgen-treated guinea pigs, reserpine did cause a
significantly small decrease in total body weight of the
guinea pig when weighed on day of sacrifice.  Androgen-
treated prepubertal castrates weighed 278.20 ± 5.65 gms. on
day of sacrifice compared to guinea pigs treated
additionally with reserpine which weighed 232.12 ± 10.93
gms.  This 16.6% difference in total body weight was not
enough to account for the 31% wet weight decrease in
seminal vesicle smooth muscle or the 42% decrease in DNA
seen in reserpine-treated animals (fig. 8).
An experiment using prepubertal guinea pigs having
undergone castration alone was done to determine whether
the decentralization, as done in the prepubertal castrates
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in the experiment above, had any effect on seminal vesicle
smooth muscle response to DHT+reserpine (fig. 9).
Figure 9: Decentralization had no significant effect on
castrate, prepubertal guinea pig seminal vesicle smooth
muscle
Figure 9: Decentralization had no significant effect on
prepubertal castrate, seminal vesicle smooth muscle
compared to castration alone.  Decentralized data were
reproduced from figure 6.  For castrate-only animals, n=14
for controls, 10 for DHT-treated groups, and 19 for
DHT+Reserpine.
Because decentralization did not effect norepinephrine
release (fig. 1), it was anticipated and recorded that
decentralization did not effect the smooth muscle response








































The down-regulation of protein kinase C (PKC) and
changes in cAMP in response to norepinephrine-depletion by
reserpine were also examined.  It has been shown that a
reduction of total PKC activity occurred in response to
androgen-induced proliferation of prepubertal guinea pig
seminal vesicle smooth muscle and was androgen-resistant in
association with the terminal differentiation seen in
adults (Mariotti et al., 1992).  Changes in PKC were
compared to changes in cAMP-dependent protein kinases which
remained androgen-sensitive in both prepubertal and adult
animals (fig. 10).
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Figure 10: The time course of androgen’s effect on PKC and
the interaction of reserpine in prepubertal castrate
seminal vesicle smooth muscle
  *
Figure 10:  Soluble PKC activity decreased with androgen
treatment.  Norepinephrine-depletion by reserpine
antagonized this effect.  Animals treated with reserpine
were treated for only 5 days due to the deleterious effects
of reserpine. n=3 with each n representing a pool of at
least 6 prepubertal animals weighing approx. 250 gms.
Control activity=473 + 19 pmol/[32P] transferred/fraction/5
mg soluble protein applied to the DEAE column.
*p < 0.05 compared to DHT-treated.
Experiments done here confirmed the down-regulation of
PKC with androgen-treatment.  Norepinephrine-depletion by
reserpine did prevent the down-regulation of PKC in
androgen-treated animals, such that the level of activity
was comparable to control animals that were not exposed to
androgen and showed no proliferation.  In contrast, cyclic-
AMP dependent type II kinase was unchanged by
norepinephrine-depletion (239.1 ± 24.1 for DHT only versus























267.3 ± 32.3 for DHT+ reserpine (units in pmol/[32P]
transferred/fraction/mg soluble protein applied to the DEAE
column)).
Figure 11: Relative amounts of PKCα as measured by
chemiluminesce
  *
Figure 11:  PKCα levels were down-regulated in prepubertal
animals with 7-day androgen treatment, yet were unchanged
in adults.  Chemiluminescence was quantified by
densitometer.  n=3.  12 µg of protein was used per well and
film was exposed for 1hour.  PKCγ, which did not change with
DHT-treatment, was used as a control.  PP=prepubertal
(approx. 250 gms).  A=Adult (800-900 gms).
*p < 0.05 compared to all other groups.
A brief examination of the immunoreactive PKCα and γ
isozymes revealed that PKCα activity in prepubertal










































PKC (fig. 10) by 7-day androgen treatment.  PKCγ was
uneffected by androgen treatment.  It was previously shown
that PKC enzymatic activity in adult castrate seminal
vesicle smooth muscle was unresponsive to androgen
treatment (Mariotti et al., 1992), as is shown in figure
11.  However, in adulthood, total PKC enzymatic activity
returned to prepubertal castrate control levels (Mariotti
et al., 1992), which was not represented in the
immunoreactive PKCα fraction.  A preliminary experiment to
determine the effect of 5-day reserpine treatment on
androgen-induced changes in PKCα was inconclusive which may
be due to differences in length of androgen administration.
No further study was conducted on PKC isozymes.
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B.  Specific Aim 2:
2.  Norepinephrine stimulated proliferation in vitro
in seminal vesicle-derived smooth muscle cells via the
α1-adrenoceptor.
The effect of fetal bovine serum (FBS) concentration
on adult guinea pig seminal vesicle smooth muscle cell
cultures was studied.  Cells were initially plated at 1 x
104 cells per flask and cultured for six days with 5%, 7.5%,
10%, or 20% FBS.  The concentration of FBS did effect cell
number with increasing FBS yielding more cells.
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Figure 12: The concentration of fetal bovine serum (FBS)
effected cell number in seminal vesicle smooth muscle
cultures
   **
  *
Figure 12: Adult normal guinea pig seminal vesicle smooth
muscle cells were plated at 1 x 104 cells per flask.
Varying concentrations of FBS were added to the media and
cells were cultured for 6 days.  n=8.
* and **: p < 0.05 compared to all other groups.
For studying the role of norepinephrine in vitro, 5%
fetal bovine serum was used.   Five percent was chosen
since it allowed for increased cell number and was not
maximal.  A maximal rate of increase in cell number due to
serum concentration was to be avoided as it may have masked
any changes due to adrenergic agents
In vitro cell culture studies support the role of
norepinephrine in male accessory sex organ smooth muscle
proliferation.  Primary cultures were made from adult






















guinea pig seminal vesicle smooth muscles.  Cells were then
passed 5 times before plating 6-well culture dishes at 1x104
cells per well and  6 x 104 cells per well.
Figure 13: The effect of plating density (1 vs. 6 x 104
cells/well) on 10 µM phenylephrine stimulation of seminal
vesicle cell culture
   *     *
    *
Figure 13:  At low density plating, cells number showed no
change from control when stimulated by 10 µM phenylephrine
(n=6 for all groups and days.) 10 µM phenylephrine
significantly enhanced cell number at high plating density.
6-well culture plates were used and media and adrenergic
agents were changed daily.
*p < 0.05 compared to control.
Cells initially plated at the higher density of 6 x 104
were counted on days 9, 11, and day 14 after treatment with
10 µM phenylephrine, an α1-adrenoceptor agonist, and
















compared to controls counted on the same days.
Phenylephrine stimulation increased cell number 44.2% on
day 9, 31.6% on day 11 and 44.6% on day 14.
Cells plated at the lower density of 1 x 104 cells per
well showed no increase in cell number by day 8 and no
difference between control and phenylephrine on day 8 as
well as subsequent days.  Some of the cells initially
plated at the lower density were maintained to day 35, with
daily media changes as was done in the earlier counts.  On
day 35, phenylephrine-treated cells showed a significant,
almost 2-fold increase over control cells.  Control cell
number remained constant from day 12 using this low serum
concentration.  Although not further pursued here, it is
possible that growth factors secreted from the cells
themselves play a role in the rate of increase of cell
number.
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Figure 14:  Cell number increases in low density (1 x 104
cells/well) plated wells
    *
Figure 14:  No difference was observed in phenylephrine-
treated cells compared to control 8, 10 and 12 days post-
plating.  With long-term maintenance (35 days), a
significant difference was seen.  6-well culture plates
were used. n=6.
*p < 0.05 compared to control.
plated at 1x104cells/well




















Figure 15: The Effect of Various Adrenergic Agents on 14-
day Seminal Vesicle Smooth Muscle Cell Culture
    *    *
       *
Figure 15:  Increased cell number was due to α1-adrenoceptor
stimulation which was blocked by prazosin, but overcome
with increased phenylephrine concentration.  Water was the
vehicle for isoproterenol.  0.1% ethanol was the vehicle
for the other agents.  Cells were initially plated at 6 x
104 cells/well (6 well plates) and maintained for 14 days.
Media and adrenergic agents were changed daily. n=3.
*p < 0.05 compared to other groups.
The use of adrenergic antagonists indicated that the
increase in cell number was due to an α1-adrenoceptor-
mediated effect.  Cells exposed to 1 µM isoproterenol, a β-
adrenoceptor agonist, had no effect on cell number compared

































































adrenoceptor was not involved in the increase in cell
number.  Furthermore, the effect of 1 µM phenylephrine was
blocked by 1 µM prazosin, an α1-adrenoceptor antagonist.
However, the antagonism caused by 1 µM prazosin could be
overcome by increasing the phenylephrine concentration to
10 µM.  These data indicated that the α1-adrenoceptor
mediated the phenylephrine-induced increase in cell number.
B.  Specific Aim 2:
2. Norepinephrine did not function anti-apoptotically
in seminal vesicle smooth muscle cells in
prepubertal castrates treated with androgen.
Previous data have shown that adult guinea pig seminal
vesicle smooth muscle exists in a terminally differentiated
state in vivo that is resistant to changes in DNA in
response to androgen ablation or repletion (Mariotti et
al., 1992).  Two findings shown above raised the
possibility that elevated NE release prevented castration-
induced regression of smooth muscle cell number in adults
through an anti-apoptotic mechanism.  NE release in adult
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castrates was 1) as high as in androgen-treated prepubertal
castrates (fig. 1) and 2) unchanged by androgen treatment
(fig. 1). Therefore, adult guinea pigs were orchiectomized
and treated with reserpine to determine whether
norepinephrine depletion would effect a net reduction in
total DNA and involve an apoptotic mechanism.
Figure 16: Norepinephrine depletion did not effect DNA in
adult seminal vesicle smooth muscle
Figure 16: Depletion of norepinephrine by reserpine had no
significant effect on µg. DNA compared to weight-matched




























In adult castrates, DNA was not effected by reserpine
treatment, precluding the proposed subsequent analysis of
apoptosis.  The potential role of apoptosis was further
pursued in androgen and reserpine-treated prepubertal
castates which exhibited a 42.4% reduction in cell number
relative to their androgen-treated control (fig. 8).
However, gel electrophoresis of nuclear extracts revealed
that neither group exhibited apoptosis.  That is, the
characteristic apoptotic laddering from DNA
oligonucleosomes was not seen in either group.  Generalized
heavy smearing indicating larger scale DNA degradation was
also not seen, ruling out necrosis.
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Figure 17: No apoptosis was detected in norepinephrine
depleted prepubertal castrates treated with androgen
   1   2    3   4   5   6   7   8   9   10   11  12  13  14
Figure 17: Lane 1 is a positive control (Kb Ladder). Lanes
2-6, and lane 13 are prepubertal castrates treated with 10
mg/kg DHT alone.  Lanes 7-12 are prepubertal castrates
treated with both DHT and 0.75 mg/kg reserpine.  Lane 14 is
an empty template, negative control.
It can be concluded that during five days of androgen
treatment, concurrent reserpine treatement did not induce
apoptosis at that point in time, despite the inhibition of
androgen-induced changes in cell number.
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C. Specific Aim 3:  Androgen decreased the number of
norepinephrine-feedback-mediating, α2-adrenoceptors in
seminal vesicle smooth muscle.
Norepinephrine was shown, in Specific Aim 2 above, to
mediate smooth muscle growth in prepubertal castrates
treated with DHT.  A potential mechanism for increased
norepinephrine release involving decreased pre-synaptic
feedback by the α2-adrenoceptor was then examined.  Other
potential mechanisms were not pursued.
As a prelude to study of the presynaptic α2-
adrenoceptor, experiments were done to determine whether
functional post-junctional α2-adrenoceptors were present.
Post-junctional α2-adrenoceptors can mediate contraction and
have been identified in dog vascular smooth muscle post-
synaptically (Langer et al., 1980).  The presence of such
receptors would preclude the use of the proposed electrical
field stimulation experiments in isolated organ baths to
study the presynaptic feedback of endogenous
norepinephrine.  By using BHT-933, a post-junctional α2-
adrenoceptor agonist (Timmermans and van Zwieten, 1980),
the presence of post-junctional α2-adrenoceptors was
studied, using contractile response as an end-point.
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Figure 18:  BHT-933 was unable to elicit post-junctional α2-
adrenoceptor-mediated contractions in adult normal guinea
pig seminal vesicle smooth muscle
 10 µM BHT-933
10 µM methoxamine 10 µM methoxamine
after 30 min.incubation
with 10-7 M prazosin
Figure 18:  10 µM BHT-933 did not elicit a post-junctional
α2-adrenoceptor mediated response.  10 µM methoxamine, an
α1-adrenoceptor agonist, + prazosin was used as a positive
control in eliciting contraction. n=4.
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BHT-933 was unable to elicit a contractile response in
seminal vesicle smooth muscle (fig. 18), even at a
supramaximal concentrations of 10 µM (Nielson et al., 1989;
Timmermans and van Zwieten, 1980), suggesting the absence
of functional post-junctional α2-adrenoceptors for this
parameter.  The smooth muscle tissues were then tested to
confirm viability with 10 µM methoxamine as a positive
control, which did elicit contractions.  These contractions
were completely blocked by prazosin (fig. 18).
Electrical field stimulation (EFS) studies of seminal
vesicle smooth muscle contraction in the presence and
absence of 1µM rauwolscine, an α2-adrenoceptor antagonist
were performed.  It was expected that rauwolscine would
block presynaptic α2-adrenoceptor-mediated norepinephrine
feedback, and thus enhance EFS-induced contractions.  The
working hypothesis was that in prepubertal castrate
animals, androgen treatment, which caused an increase in NE
release (fig. 1), would result in significant reductions in
rauwolscine-enhanced EFS contractions relative to the
prepubertal castrate control.
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Figure 19: An example of electrically field stimulated
contractile tracings from isolated seminal vesicle smooth
muscle tissues
prepubertal  prepubertal adult normal
castrate  castrate +
control         7 days DHT
prepubertal adult normal
castrate + 7days DHT after 1hr. incub.
after 30 min. in 1 µM rauwolscine
in 1 µM prazosin
Figure 19:  Only qualitative comparisons could be made due
to differences in transducer sensitivities and tissue
behavior.  Tissues were stimulated at 2, 5, 10, 20, 30 and
40 Hz for 30 seconds with each pulse being of 0.5 msec
duration. Tracings from a 40 Hz stimulation are shown
above. Prepubertal castrates showed only one contractile
peak that occurred at the moment of stimulation and was not
abolished by prazosin.  The other groups had a biphasic or
multiphasic response.  In these groups, prazosin abolished
all peaks except the initial peak.  All peaks increased
with increasing Hz.  Prepubertal guinea pigs weighed
approx. 250 gms.  Adults weighed 500-550 gms.  Each group
had an n=6-8.
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While all groups showed increasing contractile
response to increasing frequency of stimulation, inter-
group comparisons could not be made because the contractile
responses were qualitatively different.  Prepubertal
castrate controls exhibited only a single contraction in
both the control and rauwolscine-treated tissues that
occurred immediately to stimulation.  This response was not
inhibited by prazosin.  Adult normals, castrates, and
androgen-treated castrates showed a biphasic response, and
prepubertal castrates treated with dihydrotestosterone
showed multiple contractile peaks.  In all groups, prazosin
abolished all contractile responses except the initial,
very rapid upsweep of the tracing.  This initial
contraction has been described as being ATP-mediated in the
guinea pig vas deferens (Burnstock et al., 1972; Westfall
and Stitzel, 1978), and appears to be present in
prepubertal castrates as well as all of the other
experimental treatment groups.
In the groups whose tracings did show adrenergic,
contractile peaks, 1 µM rauwolscine caused enhancement to
varying degrees, indicating that the pre-synaptic α2-
adrenoceptor was functional.  The notable absence of the
functional α1-adrenoceptor-mediated contractile response in
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prepubertal castrates prevented further use of this
particular experimental design to assess changes in pre-
synaptic α2-adrenoceptor mediated effects on NE release.
The presence of a functional α1-adrenoceptor-mediated
contractile response in prepubertal castrates after
androgen-treatment, however, suggested that androgen may be
important in the development of the α1-adrenoceptor.  This
follows evidence suggested in earlier studies that the
development of α1-adrenoceptor-mediated contraction in rat
vas deferens coincided with the onset of puberty and
endogenous androgen production (MacDonald and McGrath,
1984).
The effect of α2-adrenoceptor antagonism by rauwolscine
on EFS overflow of norepinephrine was not studied.
Preliminary studies using supramaximal stimulation (40 V,
40 Hz, 30 seconds) in the presence of 1µM rauwolscine in 10
ml organ baths did not yield detectable norepinephrine
concentrations without additional extraction techniques.
Ligand binding experiments were then performed using
[3H]RX821002 to identify and quantify α2-adrenoceptors in
seminal vesicle from normal adult males (500-550 gms).
Studies to determine binding rate and protein dependence
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used 0.4 nM of tritiated ligand, the lowest concentration
to be employed in subsequent saturation analyses.
Figure 20: [3H]RX821002 binding rate and protein dependence
of [3H]RX821002-binding in adult normal guinea pig seminal
vesicle smooth muscle
Figure 20:  Binding reached equilibrium by 15 minutes, and
was linearly protein dependent between 12 and 1260 µg of
protein/200 µl when using 0.4 nM [3H]RX821002 in adult
normal guinea pigs weighing 500-550 gms.  n=4.
Using 0.4 nM [3H]RX821002, data plotted using the
GraphPad computer program, showed that a 15 minute
incubation provided for binding equilibrium.  All
subsequent experiments were done using 20 minute
incubations.  Protein dependence experiments also showed
that the femtomoles of α2-adrenoceptors bound were linearly
Binding rate




































dependent upon the amount of protein present between 12 and
1260 µg in the 200 µl reaction mixture.
Binding affinity as well as the number of sites were
determined using [3H]RX821002 concentrations ranging from
0.40 to 9.0 nM ± 10-4 M non-radioactive rauwolscine.  Results
were calculated using both saturation binding curves by
GraphPad statistical program and its linear transformation
to a Scatchard-Rosenthal plot.
92
Figure 21:  Saturation binding curves and Scatchard-
Rosenthal plots for the α2-adrenoceptor using [3H]RX821002
in normal adult guinea pig seminal vesicle smooth muscle
Figure 21: [3H]RX821002 concentrations were used ranging
from 0.40 to 9.0 nM ± 10-4 M non-radioactive rauwolscine.
Kd=0.67 ± 0.08 nM according to the saturation binding curve
and 0.65 ± 0.08 nM by Scatchard-Rosenthal linearization.
The curves depicted reflect different amounts of protein
used on each experimental day.  When corrected for protein,
Bmax=11.78 ± 1.62 fmol/mg.  Adult normal guinea pigs weighing
500-550 gms were used.
The saturation binding curve showed a Kd = 0.67 ± 0.08
nM.  The Scatchard-Rosenthal plot gave a Kd = 0.65 ± 0.08
nM.  When corrections for the varying protein amounts used
on the experimental days were made, the number of α2-
adrenoceptor binding sites (Bmax) was determined to be 11.78
± 1.62 fmol/mg membrane protein.
sat. binding































Kd comparisons can only be made to other tissues and
species since there were no other known studies using
RX821002 in guinea pig seminal vesicle smooth muscle or any
other smooth muscle specimen.  From research employing rat
cortex, spleen and kidney, and guinea pig kidney
(Erdbrugger, 1995), the Kd values were 0.6 ± 0.0, 0.4 ± 0.1,
1.5 ± 0.8, and 4.3 nM respectively.  The 0.67 nM Kd
determined in guinea pig seminal vesicle smooth muscle is
within the reported range.
Competition assays using 5 nM [3H]RX821002, a
saturating concentration, were done to characterize the
receptor subtype present.
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Table 2: Comparison of IC50’s and affinity (Ki) drugs for
the α2-adrenoceptor, using 5 nM [3H]RX821002 in adult normal
guinea pig seminal vesicle smooth muscle
    Drug  IC50    Ki
RX821002  0.67 nM(Kd from saturation experiments)
Phentolamine    220 nM       26.00 nM
Clonidine           310 nM        36.63 nM
Rauwolscine      420 nM            49.63 nM
Prazosin          35000 nM        4136 nM
Table 2: IC50’s were determined from hand-drawn, log-logit
inhibition plots, and were confirmed by curves drawn by
GraphPad computer program.  Ki’s were calculated using the
IC50’s derived by the handdrawn curves and the Cheng and
Prusoff equation, and were also confirmed by GraphPad.
Adult normal guinea pigs weighing 500-550 gms were used.
n=4.
The rank order of potency for the drugs employed above
is similar to the rank order of drugs quantified in other
tissues with α2D-adrenoceptors (Table 3).  Qualitatively,
the α2D-adrenoceptor differs from subtypes A, B, and C in
that phentolamine was a more potent antagonist than
rauwolscine (Table 3, below).
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Table 3: Ratio of Ki of competetitor to respective Kd of
RX821002 in experiments done in guinea pig seminal vesicle
smooth muscle compared to other tissues with α2D-
adrenoceptors
          seminal vesicle        bovine          rat       human clonesc
Drug           smooth muscle    irisa     pinealb   cloned 2Db      2A     2B      2C
phentolamine      38.8              48.3    9.4         9.1   14.1    6.47     35.1
rauwolscine      74.1   85.8    28.8        35.2    1.1    0.35      0.35
prazosin      6173            26241    4151       1648  1041    29.5      29.7
Table 3: a. data from Bylund (1997)
    b. data from O’Roarke (1994) and Simmonneaux(1991)
    c. data from Bylund (1992) and O’Roarke (1994)
5-hydroxytrypamine (5HT) was used to determine if
[3H]RX821002 had any interaction with serotonin receptors.
5HT at concentrations as high as 1 µM had no effect on
binding.  Since RX821002 has been shown to bind to non-
adrenergic imidazoline receptors in rabbit kidney
basolateral membranes (Coupry et al., 1987), clonidine was
used to rule out the binding of imidazoline sites.  The
notable finding was that the Ki
 
ratio of phentolamine to
clonidine was much lower in α2-adrenoceptor sites than
imidazoline sites in human brain cortex (1.52 versus 17.01)
(Miralles et al., 1993).  In the seminal vesicle smooth
muscle the clonidine to phentolamine Ki ratio was 1.38,
indicating that relative to imidazoline sites, [3H]RX821002
preferentially bound to the α2, subtype D, adrenoceptor.
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Using a single 5 nM saturating concentration of
[3H]RX821002, experiments utilized seminal vesicle smooth
muscle preparations derived from the four treatment groups
to assess potential changes in the maximal number of
binding sites relative to known changes or lack thereof in
NE release.
Figure 22: Number of α2D-adrenoceptor binding sites (Bmax) in
seminal vesicle smooth muscle among various treatment
groups.
*
 **    **
Figure 22:  The number of α2D-adrenoceptor binding sites was
reduced with androgen exposure in prepubertal seminal
vesicle smooth muscle and was unchanged by androgen in
adult tissues.  The number in parentheses is the ratio of
α2-adrenoceptor Bmax to norepinephrine released (DHPG/NE)
Prepubertal guinea pigs weighed approx. 250 gms.  Adults
weighed 500-550 gms.   Four separate experiments were done
using multiple animals in each group.
*p < 0.05 compared to prepubertal castrate control.






















The lack of contraction by BHT-933 (fig. 18) could be
assumed to be indicative of an absence of post-synaptic,
contractile-mediating α2-adrenoceptors.  Therefore, it could
be implied that any quantification of α2-adrenoceptors by
RX821002 may be more closely correlated with
norepinephrine-feedback-mediating α2-adrenoceptors.  It
appeared that androgen down-regulated the number of α2-
adrenoceptors during the proliferative, prepubertal phase
in which norepinephrine release is induced by androgen.  In
adulthood, the number of norepinephrine-feedback-mediating
α2-adrenoceptors remained low and androgen-resistant while
norepinephrine release was sustained at high levels
equivalent to androgen-treated prepubertal castrates.  This
androgen-induced decrease in the norepinephrine-feedback-
mediating, α2-adrenoceptor may be mechanistic for the
increase in norepinephrine release observed in response to
androgens in the prepubertal seminal vesicle (fig. 1).
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VI. Discussion
The goal of this research was to understand the role
of norepinephrine in the growth of male accessory sex organ
smooth muscle.  The results showed that androgen-induced
post-ganglionic norepinephrine release (fig. 1) in seminal
vesicle smooth muscle (fig. 3) and was involved in the
regulation of proliferation (fig. 8).  This increased
norepinephrine release was accompanied by down-regulation
of the α2-adrenoceptor population (fig. 22).  This
discussion will more closely explore these findings,
suggest future directions stemming from this data, and
examine the potential therapeutic significance.
In prepubertal castrates treated with androgen, smooth
muscle DNA increased 138% over control while epithelial DNA
increased 759% (fig. 8).  The androgen-induced increase in
NE release follows the time course of DNA synthesis
(Mariotti et al., 1992) and first significant increase in
total DNA.  Depletion of norepinephrine by < 99% of control
by reserpine reduced the smooth muscle increase to 37% over
control without disrupting the androgen-induced
proliferation of the cholinergically innervated epithelium.
This suggests that norepinephrine mediates the androgen-
induced proliferative response in smooth muscle.  However,
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it did not indicate whether this effect was due to enhanced
proliferation or decreased apoptosis.
It was hypothesized that the inability of castration
to reduce cell number in adult smooth muscle (Mariotti et
al., 1992) may have been due to the unexpected finding of
the sustained, androgen-resistant elevation in
norepinephrine release (fig. 1). If norepinephrine were
anti-apoptotic, reserpine-treatment would enhance apoptosis
and decrease DNA.   However, depletion of norepinephrine in
adult castrates by reserpine did not decrease cell number
relative to controls (fig. 16).  In androgen-treated
prepubertal castrates, treated concurrently with reserpine,
there was a decrease in DNA compared to androgen-treated
controls (fig. 17).  However, agarose gel electrophoresis
failed to detect any apoptotic laddering. Because apoptotic
products are quickly phagocytized (Lockshin and Beaulaton,
1974), it is possible that apoptosis had occurred at an
earlier time point and thus was undetected on the fifth day
of treatment.  Gel electrophoresis is also limited in
detecting small numbers of apoptotic nuclei.  If apoptosis
were to be further examined, double staining to detect both
in situ end labeling (ISEL) and chromatin condensation
should be employed (Tatton et al., 1998).  The onset of
androgen-induced DNA synthesis is at day 3 of treatment and
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increases in graded fashion to peak on day 7.  Androgen-
induced increases in total DNA were first detected on day 5
(based on analyses from days 3, 5, and 7 of androgen
treatment) (Mariotti et. al, 1992).  Therefore, the effect
of reserpine on androgen-induced increases in cell number
probably reflects an anti-proliferative effect.  Further
pursuit of this could explore cell cycle dependent markers
of proliferation such as Ki-67, PCNA or MIB-1 (Schipper et
al., 1998) in response to androgen + reserpine treatment.
Although there is sustained elevation of
norepinephrine release (fig. 1), seminal vesicle smooth
muscle from orchiectomized adults failed to exhibit any
change in DNA in response to androgen repletion (Mariotti
et al., 1992).  This androgen-resistant elevation of
norepinephrine release in adulthood (fig. 1) combined with
the relatively high PKC activity (Mariotti et al., 1992),
that is also androgen-resistant, indicate that increased
norepinephrine release became uncoupled from the mitogenic
response at or before the level of stable activation of
PKC.  Specifically, with the onset of androgen-exposure in
prepubertal castrates, seminal vesicle smooth muscle
norepinephrine release was upregulated and maintained into
adulthood when it was androgen-resistant (fig. 1).  PKC was
stablely activated then down regulated in androgen-treated
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prepubertal castrates.  However, in adulthood, PKC returns
to the elevated, prepubertal castrate control levels in
association with differentiation to an amitotic state
(Mariotti et al., 1992).  This uncoupling of increased
norepinephrine release from PKC activation and subsequent
depletion appears to be a critical event in the resistance
to proliferation demonstrated in adult smooth muscle.
Future investigation focusing on the mechanism of PKC
resistance to α1-adrenoceptor stimulation should provide
pertinent information about the normal terminal
differentiation process of this androgen sensitive smooth
muscle.
Prepubertally, before uncoupling of norepinephrine and
PKC occurs, norepinephrine depletion by reserpine can
prevent the androgen-induced down-regulation of PKC (fig.
10).  Androgen down-regulated PKCα in prepubertal castrates
(fig. 11), but in adulthood, the α-isozyme did not return
to prepubertal castrate control levels as has been
demonstrated with PKC (Mariotti et al., 1992).  However, it
is possible that this discrepancy is due to differences in
quantification methods.  Immunochemilumiscence was employed
to determine isozyme quantities while enzymatic activity
was employed to quantify PKC.
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The androgen-dependent down-regulation of α2-
adrenoceptors (fig.22) may be a potential mechanism for
increased norepinephrine release.  However, whether these
analyses actually represent pre-synaptic α2-adrenoceptors
that mediate the feedback inhibition of norepinephrine
release, remains to be determined.  Studies of BHT-933
effects failed to identify post-junctional α2-adrenoceptor
mediated smooth muscle contraction (fig. 18), but the
failure to detect these post-junctional receptors does not
rule out extraneuronal binding sites.  Future studies
should be pursued to determine whether a cause and effect
relationship exists between the increased norepinephrine
release and decreased α2-adrenoceptor population during
growth of smooth muscle cells.  Ex vivo electrical field
stimulation studies to measure increased norepinephrine
release under conditions in which α2-adrenoceptor agonist
and antagonist effects can be quantified should provide
more relevant insight into the role of the pre-synaptic
receptor and norepinephrine release.  Pursuit of these
experiments may require the use of reuptake inhibitors and
an organ bath designed with minimal volume to allow for
norepinephrine measurement with graded electrical field
stimulation rather than supramaximal and prolonged
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stimulation commonly employed for these types of
experiments (LaPierre et al., 1993; Ventura et al., 1998).
A major area for future examination is the potential
role of the extracellular matrix in proliferation.  The
cell culture experiments performed here suggest
extracellular factors may be involved. In vivo adult smooth
muscle does not proliferate in response to androgen and the
elevated endogenous release of norepinephrine.  Yet, adult
seminal vesicle smooth muscle cells proliferated in culture
and were sensitive to the mitogenic effects of
phenylephrine (fig. 13, 14, and 15).  Cell number also
increased at varying rates that appear to be dependent upon
the plating density and confluence (fig. 13 and 14).
This change to a proliferative state in culture may be
due to a decrease in anti-proliferative extracellular
matrix heparan sulfate proteoglycans.  Neonatal or
neointimal matrices have been shown to stimulate vascular
smooth muscle cell growth more efficiently than matrix from
adult cells (Hein et al., 1996).  This growth was further
increased by the enzymatic digestion of extracellular
matrix heparan sulfate (Hein et al., 1996).  Heparan
sulfate proteoglycans have the potential to function as
growth inhibitors (Castellot et al., 1981; Bingley et al.,
1998) in vascular smooth muscle cell cultures and can
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prevent neointimal formation in vivo (Bingley et al.,
1998). An eight-fold greater anti-proliferative potency was
measured for cell surface heparan sulfate proteoglycans
extracted during confluence as compared to the exponential
growth or postconfluent phases (Fritze et al., 1985).
While the anti-proliferative effect of heparan sulfate has
not been clearly elucidated, heparin, a molecule closely
related to heparan sulfate, can inhibit PKC activity in
intact cells (Feige et al., 1989).  It has also been shown
in mixed micellar assays that heparan sulfate is a weak
inhibitor of PKC (Herbert and Maffrand, 1991).  These
observations raise the possibility that the resistance in
vivo to proliferation in adult seminal vesicle smooth
muscle, which involves PKC resistance to α1-adrenoceptor
stimulation, may be linked to the expression of cell
surface anti-proliferative heparan sulfate proteoglycans.
Lastly, the possible therapeutic significance of this
work should be recognized.  Depletion of norepinephrine by
reserpine in vivo in prepubertal castrates selectively
perturbed the androgen-induced increase in smooth muscle
mass and DNA (fig. 8).  This, along with other evidence
accrued in this work, indicates that norepinephrine does
indeed play an obligatory role in androgen-induced
proliferation.  Importantly, only the smooth muscle was
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inhibited.  The epithelium was not effected by reserpine.
This is the first demonstration of selective antagonism of
androgen-induced increases in DNA in accessory sex organ
smooth muscle.  While systemic reserpine treatment could
not be used therapeutically for BPH due to multiple
systemic adverse effects, the principle has been
established that it is pharmacologically feasible to
inhibit androgen-induced growth of seminal vesicle smooth
muscle without perturbing the epithelium.  Future studies
should be performed to determine whether the inhibition of
the proliferative response by short-term reserpine
treatment in the presence of sustained androgenic
stimulation is irreversible.  Selective inhibition of the
mitogenic response without antagonism of the
differentiating effects of androgen may result in
irreversible and premature cessation of smooth muscle
growth.  This experiment could be particularly enlightening
regarding the future development of short term therapies in
young adults that could prevent symptomatic BPH in men 60
years of age and older.
In addition, if α2-adrenoceptor agonists decrease
norepinephrine release and inhibit androgen-induced smooth
muscle proliferation, attempts could be made to
pharmacologically upregulate the expression of the pre-
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synaptic, norepinephrine-feedback-mediating α2-adrenoceptor.
Understanding the sequencing of the promoter region of the
α2-adrenoceptor gene could lead to the rational development
of ligands to possibly maintain irreversible expression at
high levels.  Theoretically, such compounds may include
neurosteroids that could selectively upregulate pre-
synaptic α2-adrenoceptor expression without stimulating
androgen receptor mediated male accessory sex organ smooth
muscle growth.  For example, progesterone has been found to
be derived from rat glial cells in culture (Jung-Testas et
al., 1989) and functions to modulate GABAergic transmission
in the central nervous system (Mahesh et al., 1996).
Hammond (1978) has identified progesterone in the human
prostate at concentrations (0.39 ± 0.07 ng/g tissue) in the
same range as the biologically active androgens,
testosterone (0.25 ± 0.04 ng/g tissue) and
dihydrotestosterone (1.22 ± 0.14 ng/g tissue).  However, no
biological role of this steroid in male accessory sex organ
has been elucidated to date.  The idea that endogenous
steroids with neurospecific effects may exist within male
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